PT772619E - Oligonucleotidos imunomoduladores - Google Patents

Oligonucleotidos imunomoduladores

Info

Publication number: PT772619E
Authority: PT; Portugal
Prior art keywords: oligonucleotidos; imunomoduladores; stabilised; contain; cpg dinucleotide
Prior art date: 1994-07-15

Application number

PT95911630T

Other languages

English (en)

Inventor

Arthur M Krieg

Klinman Dennis

Alfred D Steinberg

Original Assignee

Univ Iowa Res Found

Us Health

Ry Dept Of Health And Human Se

Coley Pharm Group Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-15

Filing date

1995-02-07

Publication date

2006-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23056334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT772619(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-02-07 Application filed by Univ Iowa Res Found, Us Health, Ry Dept Of Health And Human Se, Coley Pharm Group Inc filed Critical Univ Iowa Res Found

2006-10-31 Publication of PT772619E publication Critical patent/PT772619E/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurosurgery (AREA)
Tropical Medicine & Parasitology (AREA)
Analytical Chemistry (AREA)
Neurology (AREA)
Plant Pathology (AREA)
Mycology (AREA)
Dermatology (AREA)
Rheumatology (AREA)

PT95911630T 1994-07-15 1995-02-07 Oligonucleotidos imunomoduladores PT772619E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US27635894A	1994-07-15	1994-07-15

Publications (1)

Publication Number	Publication Date
PT772619E true PT772619E (pt)	2006-10-31

Family

ID=23056334

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT95911630T PT772619E (pt)	1994-07-15	1995-02-07	Oligonucleotidos imunomoduladores

Country Status (12)

Country	Link
US (1)	US6194388B1 (pt)
EP (4)	EP1167377B2 (pt)
JP (7)	JP3468773B2 (pt)
AT (3)	ATE420171T1 (pt)
AU (1)	AU713040B2 (pt)
CA (2)	CA2560114A1 (pt)
DE (2)	DE69535036T3 (pt)
DK (1)	DK0772619T4 (pt)
ES (3)	ES2366201T3 (pt)
HK (3)	HK1043598A1 (pt)
PT (1)	PT772619E (pt)
WO (1)	WO1996002555A1 (pt)

Families Citing this family (879)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5849719A (en)	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
US6727230B1 (en)	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US7935675B1 (en) *	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6429199B1 (en) *	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
CA2560114A1 (en) *	1994-07-15	1996-02-01	The University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US7422902B1 (en) *	1995-06-07	2008-09-09	The University Of British Columbia	Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) *	1995-06-07	1999-11-09	Inex Pharmaceuticals Corp.	Methods for encapsulating plasmids in lipid bilayers
EP0909323B1 (en)	1996-01-04	2007-02-28	Novartis Vaccines and Diagnostics, Inc.	Helicobacter pylori bacterioferritin
CA2244946C (en) *	1996-01-30	2010-04-13	The Regents Of The University Of California	Gene expression vectors which generate an antigen specific immune response and methods of using the same
FR2750704B1 (fr)	1996-07-04	1998-09-25	Rhone Poulenc Rorer Sa	Procede de production d'adn therapeutique
US5856462A (en) *	1996-09-10	1999-01-05	Hybridon Incorporated	Oligonucleotides having modified CpG dinucleosides
AU768178B2 (en) *	1996-10-11	2003-12-04	Regents Of The University Of California, The	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6610661B1 (en)	1996-10-11	2003-08-26	The Regents Of The University Of California	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0855184A1 (en) *	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
EP1039935A4 (en) *	1997-02-28	2005-04-27	Univ Iowa Res Found	USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
EP2172216A3 (en) *	1997-03-10	2010-11-24	Ottawa Hospital Research Institute	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en)	1997-04-30	2002-07-30	Hybridon, Inc.	Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US20030104044A1 (en) *	1997-05-14	2003-06-05	Semple Sean C.	Compositions for stimulating cytokine secretion and inducing an immune response
EP1027033B1 (en)	1997-05-14	2009-07-22	The University Of British Columbia	High efficiency encapsulation of nucleic acids in lipid vesicles
WO1998052962A1 (en) *	1997-05-19	1998-11-26	Merck & Co., Inc.	Oligonucleotide adjuvant
ATE370740T1 (de)	1997-05-20	2007-09-15	Ottawa Health Research Inst	Verfahren zur herstellung von nukleinsäurekonstrukten
EP2085090A3 (en) *	1997-06-06	2012-05-02	The Regents of the University of California	Inhibitors of DNA immunostimulatory sequence activity
US6589940B1 (en)	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) *	1998-06-05	2004-01-08	Eyal Raz	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
EP1374894A3 (en) *	1997-06-06	2004-09-22	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
PT1009413E (pt) *	1997-09-05	2007-05-31	Univ California	Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma.
GB9724531D0 (en)	1997-11-19	1998-01-21	Smithkline Biolog	Novel compounds
PT1584685E (pt)	1998-02-05	2011-06-17	Glaxosmithkline Biolog Sa	Derivados de antigénios associados a tumores da família mage, utilizados para a preparação de proteínas de fusão com epítopos auxiliares t e de composições para vacinação
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
CA2323929C (en) *	1998-04-03	2004-03-09	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO1999052549A1 (en) *	1998-04-09	1999-10-21	Smithkline Beecham Biologicals S.A.	Adjuvant compositions
GB9808866D0 (en)	1998-04-24	1998-06-24	Smithkline Beecham Biolog	Novel compounds
WO1999056755A1 (en) *	1998-05-06	1999-11-11	University Of Iowa Research Foundation	Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
ATE305507T1 (de) *	1998-05-14	2005-10-15	Coley Pharm Gmbh	Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide
EP1079824B1 (en)	1998-05-19	2011-08-31	RESEARCH DEVELOPMENT FOUNDATION (a Nevada corporation)	Triterpene compositions and methods for use thereof
IL139813A0 (en) *	1998-05-22	2002-02-10	Loeb Health Res Inst At The Ot	Methods and products for inducing mucosal immunity
US6881561B1 (en)	1998-05-27	2005-04-19	Cheil Jedang Corporation	Endonuclease of immune cell, process for producing the same and immune adjuvant using the same
KR19990086271A (ko) *	1998-05-27	1999-12-15	손경식	면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제
US6562798B1 (en)	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20040247662A1 (en) *	1998-06-25	2004-12-09	Dow Steven W.	Systemic immune activation method using nucleic acid-lipid complexes
US6693086B1 (en) *	1998-06-25	2004-02-17	National Jewish Medical And Research Center	Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) *	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
WO2000006588A1 (en) *	1998-07-27	2000-02-10	University Of Iowa Research Foundation	STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
CA2337743C (en)	1998-07-31	2015-07-07	Yoshihiro Oka	Tumor antigen based on products of the tumor suppressor gene wt1
DK2272859T3 (en)	1998-08-07	2015-01-19	Univ Washington	Immunological herpes simplex virus antigens and methods for their use
AU773204C (en) *	1998-08-10	2005-05-19	Antigenics Llc	Compositions of CPG and saponin adjuvants and methods thereof
EP1109924A2 (en) *	1998-09-09	2001-06-27	Genzyme Corporation	Methylation of plasmid vectors
US6692752B1 (en)	1999-09-08	2004-02-17	Smithkline Beecham Biologicals S.A.	Methods of treating human females susceptible to HSV infection
FR2783170B1 (fr) *	1998-09-11	2004-07-16	Pasteur Merieux Serums Vacc	Emulsion immunostimulante
AU766492B2 (en) *	1998-09-18	2003-10-16	Dynavax Technologies Corporation	Methods of treating IgE-associated disorders and compositions for use therein
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
JP2002526425A (ja) *	1998-10-05	2002-08-20	ザリージェンツオブザユニバーシティオブカリフォルニア	粘膜免疫を刺激するための方法およびアジュバント
DK1126876T3 (da)	1998-10-16	2007-07-02	Glaxosmithkline Biolog Sa	Adjuvanssystemer og vacciner
ES2374055T3 (es)	1998-12-08	2012-02-13	Glaxosmithkline Biologicals S.A.	Nuevos compuestos derivados de neisseria meningitidis.
TR200102500T2 (tr)	1998-12-08	2002-03-21	Corixa Corporation	Chlamydia enfeksiyonunu tedavi etmek iin bileçikler.
US20020119158A1 (en)	1998-12-17	2002-08-29	Corixa Corporation	Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en)	1998-12-28	2003-06-17	Corixa Corporation	Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7083796B2 (en)	2000-06-20	2006-08-01	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis
US7198920B1 (en)	1999-01-29	2007-04-03	Corika Corporation	HER-2/neu fusion proteins
JP2002536344A (ja) *	1999-02-05	2002-10-29	ジエンザイムコーポレイション	抗腫瘍免疫を発生させるためのカチオン性脂質の使用
EP2204186B1 (en)	1999-02-17	2016-04-06	CSL Limited	Immunogenic complexes and methods relating thereto
US8206749B1 (en)	1999-02-26	2012-06-26	Novartis Vaccines And Diagnostics, Inc.	Microemulsions with adsorbed macromolecules and microparticles
JP4812942B2 (ja)	1999-02-26	2011-11-09	ノバルティスヴァクシンズアンドダイアグノスティクスエスアールエル	ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
WO2000055327A2 (en)	1999-03-12	2000-09-21	Smithkline Beecham Biologicals S.A.	Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
FR2790955B1 (fr) *	1999-03-19	2003-01-17	Assist Publ Hopitaux De Paris	Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
JP2000262247A (ja) *	1999-03-19	2000-09-26	Asama Kasei Kk	免疫調節剤、免疫調節食品および免疫調節飼料
IL145043A0 (en)	1999-03-19	2002-06-30	Smithkline Beecham Biolog	Vaccine
GB9909077D0 (en)	1999-04-20	1999-06-16	Smithkline Beecham Biolog	Novel compositions
EP1169347B1 (en)	1999-04-02	2008-07-02	Corixa Corporation	Compounds and methods for therapy and diagnosis of lung cancer
US6977245B2 (en) *	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
EP1176966B1 (en)	1999-04-12	2013-04-03	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Oligodeoxynucleotide and its use to induce an immune response
US6558670B1 (en)	1999-04-19	2003-05-06	Smithkline Beechman Biologicals S.A.	Vaccine adjuvants
TR200103018T2 (tr) *	1999-04-19	2002-02-21	Beecham Biologicals S.A. Smithkline	İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
AU4978100A (en) *	1999-04-29	2000-11-17	Coley Pharmaceutical Gmbh	Screening for immunostimulatory dna functional modifyers
GB9915204D0 (en) *	1999-06-29	1999-09-01	Smithkline Beecham Biolog	Vaccine
CA2376992A1 (en) *	1999-06-29	2001-01-04	Smithkline Beecham Biologicals S.A.	Use of cpg as an adjuvant for hiv vaccine
US6514948B1 (en)	1999-07-02	2003-02-04	The Regents Of The University Of California	Method for enhancing an immune response
FR2795963A1 (fr) *	1999-07-08	2001-01-12	Pasteur Merieux Serums Vacc	Polynucleotide immunostimulant
SK782002A3 (en) *	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
GB9918319D0 (en)	1999-08-03	1999-10-06	Smithkline Beecham Biolog	Vaccine composition
US20050226890A1 (en) *	1999-08-12	2005-10-13	Cohen David I	Tat-based vaccine compositions and methods of making and using same
DE60041335D1 (de) *	1999-08-19	2009-02-26	Dynavax Tech Corp	Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür
CZ20021029A3 (cs) *	1999-08-27	2002-08-14	Inex Pharmaceuticals Corp.	Kompozice a její pouľití pro stimulaci sekrece cytokinů a indukci imunitní odpovědi
UA77152C2 (en) *	1999-09-25	2006-11-15		Method for stimulation of immune response using nucleic acid-containing immunostimulating compositions, method for treatment of cancer and method for treatment or prophylaxis of allergy or asthma
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
JP4540033B2 (ja)	1999-10-22	2010-09-08	サノフィパストゥールリミテッド	腫瘍抗原に対する免疫応答を誘発および／または増強する方法
US7223398B1 (en)	1999-11-15	2007-05-29	Dynavax Technologies Corporation	Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
AU2593701A (en) *	1999-12-21	2001-07-03	Regents Of The University Of California, The	Method for preventing an anaphylactic reaction
DE60131430T2 (de) *	2000-01-14	2008-10-16	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
AT409085B (de) *	2000-01-28	2002-05-27	Cistem Biotechnologies Gmbh	Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
WO2001055341A2 (en) *	2000-01-31	2001-08-02	The Regents Of The University Of California	Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en) *	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
FR2805264B1 (fr) *	2000-02-18	2002-04-12	Aventis Pasteur	Oligonucleotides immunostimulants
FR2805265B1 (fr) *	2000-02-18	2002-04-12	Aventis Pasteur	Oligonucleotides immunostimulants
AU2001241751B2 (en)	2000-02-23	2005-09-01	Tel Aviv Sourasky Medical Center	Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
KR100919916B1 (ko) *	2000-02-23	2009-10-07	글락소스미스클라인 바이오로지칼즈 에스.에이.	종양 특이적 동물 단백질
US20030130217A1 (en) *	2000-02-23	2003-07-10	Eyal Raz	Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20040002068A1 (en)	2000-03-01	2004-01-01	Corixa Corporation	Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040131628A1 (en) *	2000-03-08	2004-07-08	Bratzler Robert L.	Nucleic acids for the treatment of disorders associated with microorganisms
US20010046967A1 (en)	2000-03-10	2001-11-29	Gary Van Nest	Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US7157437B2 (en)	2000-03-10	2007-01-02	Dynavax Technologies Corporation	Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US7129222B2 (en) *	2000-03-10	2006-10-31	Dynavax Technologies Corporation	Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en)	2000-03-10	2003-07-10	Gary Van Nest	Biodegradable immunomodulatory formulations and methods for use thereof
US20020098199A1 (en)	2000-03-10	2002-07-25	Gary Van Nest	Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
CA2405424A1 (en) *	2000-04-07	2001-10-18	The Regents Of The University Of California	Synergistic improvements to polynucleotide vaccines
US20030175700A1 (en)	2000-04-21	2003-09-18	Ajay Bhatia	Compounds and methods for treatment and diagnosis of chlamydial infection
EP1741782B1 (en)	2000-05-10	2011-06-22	Sanofi Pasteur Limited	Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
CA2409221C (en)	2000-05-19	2010-10-26	Corixa Corporation	Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
DE60139689D1 (de)	2000-06-22	2009-10-08	Univ Iowa Res Found	Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
WO2002000174A2 (en)	2000-06-28	2002-01-03	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
HU227893B1 (en)	2000-06-29	2012-05-29	Glaxosmithkline Biolog Sa	Vaccine compositions
GB0108364D0 (en)	2001-04-03	2001-05-23	Glaxosmithkline Biolog Sa	Vaccine composition
US7229623B1 (en)	2000-08-03	2007-06-12	Corixa Corporation	Her-2/neu fusion proteins
KR100917101B1 (ko) *	2000-08-04	2009-09-15	도요 보세키 가부시키가이샤	플렉시블 금속적층체 및 그 제조방법
UA79735C2 (uk)	2000-08-10	2007-07-25	Глаксосмітклайн Байолоджікалз С.А.	Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
US20080044435A1 (en) *	2004-03-16	2008-02-21	Cohen David I	Tat-Based Tolerogen Compositions and Methods of Making and Using Same
AU2001285421A1 (en) *	2000-08-10	2002-02-18	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Vaccine against rsv
EP1335741A4 (en) *	2000-08-25	2005-10-26	Yeda Res & Dev	METHOD FOR THE PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDES (04.03.02)
GB0022742D0 (en)	2000-09-15	2000-11-01	Smithkline Beecham Biolog	Vaccine
ATE510850T1 (de) *	2000-09-15	2011-06-15	Coley Pharm Gmbh	Verfahren zum hochdurchsatzscreening von auf cpg basierenden immunagonisten und -antagonisten
DE60131670T2 (de)	2000-10-18	2008-10-30	Glaxosmithkline Biologicals S.A.	Impfstoffe gegen Krebskrankheiten
IL154853A0 (en)	2000-10-27	2003-10-31	Chiron Spa	Nucleic acids and proteins from streptococcus groups a & b
ES2307568T3 (es) *	2000-12-08	2008-12-01	Coley Pharmaceutical Gmbh	Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US6677347B2 (en) *	2000-12-08	2004-01-13	3M Innovative Properties Company	Sulfonamido ether substituted imidazoquinolines
CA2598144A1 (en) *	2000-12-08	2006-08-31	3M Innovative Properties Company	Compositions and methods for targeted delivery of immune response modifiers
KR100881923B1 (ko) *	2000-12-27	2009-02-04	다이나박스 테크놀로지 코퍼레이션	면역자극 폴리뉴클레오티드 및 그것의 사용 방법
WO2002055090A1 (fr) *	2001-01-12	2002-07-18	Amato Pharmaceutical Products,Ltd.	Agents preventifs d'infections microbiennes
KR20030070102A (ko) *	2001-01-12	2003-08-27	아마토 세이야쿠 가부시키가이샤	항알레르기제
US7128911B2 (en)	2001-01-19	2006-10-31	Cytos Biotechnology Ag	Antigen arrays for treatment of bone disease
EP1362594A1 (en) *	2001-01-24	2003-11-19	Amato Pharmaceutical Products, Ltd.	Anti-stress agents
DE10105234A1 (de)	2001-02-02	2002-08-29	Schoeller Textil Ag Sevelen	Textile Fläche
GB0103171D0 (en)	2001-02-08	2001-03-28	Smithkline Beecham Biolog	Vaccine composition
GB0105360D0 (en) *	2001-03-03	2001-04-18	Glaxo Group Ltd	Chimaeric immunogens
JP3728439B2 (ja)	2001-03-22	2005-12-21	治夫杉山	Ｗｔ１改変ペプチド
US20030050268A1 (en) *	2001-03-29	2003-03-13	Krieg Arthur M.	Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
JP2005504513A (ja)	2001-05-09	2005-02-17	コリクサコーポレイション	前立腺癌の治療及び診断のための組成物及び方法
WO2002094845A2 (en)	2001-05-21	2002-11-28	Intercell Ag	Method for stabilising of nucleic acids
US6818787B2 (en) *	2001-06-11	2004-11-16	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
US7785610B2 (en) *	2001-06-21	2010-08-31	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same—III
AU2002345847B2 (en) *	2001-06-21	2008-05-29	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same
CA2451739A1 (en) *	2001-06-29	2003-01-09	Chiron Corporation	Hcv e1e2 vaccine compositions
CA2452382A1 (en)	2001-07-10	2003-01-23	Corixa Corporation	Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
GB0118249D0 (en)	2001-07-26	2001-09-19	Chiron Spa	Histidine vaccines
GB0121591D0 (en)	2001-09-06	2001-10-24	Chiron Spa	Hybrid and tandem expression of neisserial proteins
US7666674B2 (en)	2001-07-27	2010-02-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002318944A1 (en) *	2001-08-01	2003-02-17	Coley Pharmaceutical Gmbh	Methods and compositions relating to plasmacytoid dendritic cells
JP2005518343A (ja) *	2001-08-03	2005-06-23	メダレックス，インク．	新規なｐｇｃ−１イソフォームおよびその使用媒介型免疫治療を向上させるためのその使用
CA2456328C (en) *	2001-08-07	2015-05-26	Dynavax Technologies Corporation	Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof
US7354909B2 (en) *	2001-08-14	2008-04-08	The United States Of America As Represented By Secretary Of The Department Of Health And Human Services	Method for rapid generation of mature dendritic cells
US7361352B2 (en)	2001-08-15	2008-04-22	Acambis, Inc.	Influenza immunogen and vaccine
AU2002331643B2 (en) *	2001-08-17	2007-10-11	Coley Pharmaceutical Gmbh	Combination motif immune stimulatory oligonucleotides with improved activity
US7282476B2 (en)	2001-08-24	2007-10-16	University Of Victoria Innovation And Development Corporation	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
JP2005501550A (ja) *	2001-08-30	2005-01-20	スリーエムイノベイティブプロパティズカンパニー	免疫反応調整剤分子を用いた形質細胞様樹状細胞を成熟させる方法
BR0212366A (pt) *	2001-09-07	2004-07-27	Univ Boston	Método e composição para tratar distúrbios associados com o complexo imune
CA2492823A1 (en) *	2001-09-14	2003-03-27	Martin F. Bachmann	In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP2196217A1 (en)	2001-09-14	2010-06-16	Cytos Biotechnology AG	Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
JP4601956B2 (ja)	2001-09-20	2010-12-22	グラクソグループリミテッド	Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン
WO2003027313A2 (en)	2001-09-24	2003-04-03	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US20030119774A1 (en) *	2001-09-25	2003-06-26	Marianna Foldvari	Compositions and methods for stimulating an immune response
WO2003028757A1 (en) *	2001-09-28	2003-04-10	Haruo Sugiyama	Novel method of inducing antigen-specific t cells
JPWO2003028758A1 (ja) *	2001-09-28	2005-01-13	治夫杉山	抗原特異的ｔ細胞の誘導方法
AR045702A1 (es)	2001-10-03	2005-11-09	Chiron Corp	Composiciones de adyuvantes.
EP1451581A4 (en) *	2001-10-05	2006-01-11	Coley Pharm Gmbh	AGONISTS AND ANTAGONISTS OF THE SIGNALING OF THE GREAT-SIMILAR RECEPTOR 3
JP2005519990A (ja) *	2001-10-12	2005-07-07	ユニバーシティオブアイオワリサーチファウンデーション	イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物
TW200303759A (en) *	2001-11-27	2003-09-16	Schering Corp	Methods for treating cancer
AU2002358616A1 (en) *	2001-12-07	2003-06-17	Intercell Ag	Immunostimulatory oligodeoxynucleotides
WO2003050241A2 (en)	2001-12-12	2003-06-19	The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services	Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
DK2224012T3 (da)	2001-12-17	2013-05-13	Corixa Corp	Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
US7615227B2 (en) *	2001-12-20	2009-11-10	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of CpG oligodeoxynucleotides to induce angiogenesis
US8466116B2 (en)	2001-12-20	2013-06-18	The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of CpG oligodeoxynucleotides to induce epithelial cell growth
WO2003055514A1 (en) *	2001-12-21	2003-07-10	Antigenics Inc.	Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
US20040034223A1 (en) *	2002-02-07	2004-02-19	Covalent Partners, Llc.	Amphiphilic molecular modules and constructs based thereon
WO2003067286A2 (en) *	2002-02-07	2003-08-14	Covalent Partners, Llc	Nanofilm and membrane compositions
US8088388B2 (en) *	2002-02-14	2012-01-03	United Biomedical, Inc.	Stabilized synthetic immunogen delivery system
EP2572707A3 (en)	2002-02-20	2013-11-06	Novartis Vaccines and Diagnostics, Inc.	Microparticles with adsorbed polypeptide-containing molecules
US7351413B2 (en) *	2002-02-21	2008-04-01	Lorantis, Limited	Stabilized HBc chimer particles as immunogens for chronic hepatitis
EP2258712A3 (en)	2002-03-15	2011-05-04	Multicell Immunotherapeutics, Inc.	Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
US20070037769A1 (en) *	2003-03-14	2007-02-15	Multicell Immunotherapeutics, Inc.	Compositions and methods to treat and control tumors by loading antigen presenting cells
CA2479187A1 (en) *	2002-03-15	2003-09-25	Astral, Inc.	Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
ES2734652T3 (es)	2002-04-04	2019-12-11	Zoetis Belgium S A	Oligorribonucleótidos inmunoestimulantes que contienen G y U
US20030224013A1 (en) *	2002-04-19	2003-12-04	Cole Garry T.	Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
US20040013649A1 (en) *	2002-05-10	2004-01-22	Inex Pharmaceuticals Corporation	Cancer vaccines and methods of using the same
JP2005530761A (ja) *	2002-05-10	2005-10-13	イネックスファーマシューティカルズコーポレイション	癌ワクチン及びその使用方法
US20040009944A1 (en) *	2002-05-10	2004-01-15	Inex Pharmaceuticals Corporation	Methylated immunostimulatory oligonucleotides and methods of using the same
US20040009943A1 (en) *	2002-05-10	2004-01-15	Inex Pharmaceuticals Corporation	Pathogen vaccines and methods for using the same
KR100456681B1 (ko) *	2002-05-22	2004-11-10	주식회사 대웅	박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
CA2388049A1 (en)	2002-05-30	2003-11-30	Immunotech S.A.	Immunostimulatory oligonucleotides and uses thereof
AU2003243409A1 (en) *	2002-06-05	2003-12-22	Coley Pharmaceutical Group, Inc.	Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
SE0201701D0 (sv) *	2002-06-05	2002-06-05	Gotovax Ab	Treatment of epithelial tumors and infections
ATE489969T1 (de) *	2002-06-20	2010-12-15	Cytos Biotechnology Ag	Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
WO2004002500A1 (en)	2002-06-28	2004-01-08	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
US7569553B2 (en) *	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) *	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) *	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
DE10229872A1 (de)	2002-07-03	2004-01-29	Curevac Gmbh	Immunstimulation durch chemisch modifizierte RNA
US7605138B2 (en) *	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) *	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
AU2003255969A1 (en) *	2002-07-17	2004-02-02	Coley Pharmaceutical Gmbh	Use of cpg nucleic acids in prion-disease
CA2492598C (en)	2002-07-18	2013-12-17	University Of Washington	Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
WO2004011650A2 (en)	2002-07-24	2004-02-05	Intercell Ag	Antigens encoded by alternative reading frame from pathogenic viruses
AU2003263963A1 (en)	2002-08-01	2004-02-23	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
AU2003260357B2 (en)	2002-08-02	2009-10-29	Glaxosmithkline Biologicals S.A.	Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB- Neisseria minigitidis
DK1545597T3 (da)	2002-08-15	2011-01-31	3M Innovative Properties Co	Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
GB0220194D0 (en)	2002-08-30	2002-10-09	Chiron Spa	Improved vesicles
EP2402026A3 (en)	2002-09-13	2012-04-18	Intercell AG	Method for isolating hepatitis C virus peptides
US20040106741A1 (en) *	2002-09-17	2004-06-03	Kriesel Joshua W.	Nanofilm compositions with polymeric components
US8263091B2 (en) *	2002-09-18	2012-09-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
WO2004031382A1 (ja) *	2002-10-02	2004-04-15	Mochida Pharmaceutical Co., Ltd.	新規なモノクローナル抗体の作製方法
US8043622B2 (en)	2002-10-08	2011-10-25	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
WO2004035618A2 (en)	2002-10-15	2004-04-29	Intercell Ag	Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
EP1569515A4 (en)	2002-10-23	2006-04-26	Glaxosmithkline Biolog Sa	MALARIA vaccine method
CA2503457A1 (en) *	2002-10-25	2004-05-06	University Of Connecticut Health Center	Apparatus and method for immunotherapy of a cancer through controlled cell lysis
CN101948835A (zh)	2002-10-29	2011-01-19	科勒制药集团股份有限公司	Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
CA2504493C (en) *	2002-11-01	2015-12-29	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
WO2004046177A2 (en)	2002-11-15	2004-06-03	Chiron Srl	Unexpected surface proteins in neisseria meningitidis
EP2329827A3 (en) *	2002-11-21	2011-07-13	Bayhill Therapeutics, Inc.	Methods and immune modulatory nucleic acid compositions for preventing and treating disease
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
US20050287170A1 (en) *	2002-12-11	2005-12-29	Hawaii Biotech, Inc.	Subunit vaccine against West Nile viral infection
US20040213808A1 (en) *	2002-12-11	2004-10-28	Michael Lieberman	Recombinant vaccine against flavivirus infection
JP2006512927A (ja) *	2002-12-11	2006-04-20	コーリーファーマシューティカルグループ，インコーポレイテッド	５’ｃｐｇ核酸およびその使用方法
KR100525321B1 (ko) *	2002-12-13	2005-11-02	안웅식	파필로마바이러스 항원 단백질 및ＣｐＧ-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물
EP1625140A4 (en) *	2002-12-23	2008-06-18	Dynavax Tech Corp	BRANCHED IMMUNOMODULAR COMPOUNDS AND METHOD OF USE THEREOF
CN101693890B (zh) *	2002-12-23	2012-09-05	戴纳伐克斯技术股份有限公司	免疫刺激序列寡核苷酸和使用方法
US8158768B2 (en)	2002-12-23	2012-04-17	Dynavax Technologies Corporation	Immunostimulatory sequence oligonucleotides and methods of using the same
WO2004060396A2 (en)	2002-12-27	2004-07-22	Chiron Corporation	Immunogenic compositions containing phospholpid
EP2572715A1 (en)	2002-12-30	2013-03-27	3M Innovative Properties Company	Immunostimulatory Combinations
US7960522B2 (en)	2003-01-06	2011-06-14	Corixa Corporation	Certain aminoalkyl glucosaminide phosphate compounds and their use
CN101863930A (zh)	2003-01-06	2010-10-20	科里克萨有限公司	一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途
AU2004209660A1 (en)	2003-02-03	2004-08-19	Fraunhofer Usa, Inc.	System for expression of genes in plants
WO2004071459A2 (en) *	2003-02-13	2004-08-26	3M Innovative Properties Company	Methods and compositions related to irm compounds and toll-like receptor 8
AU2004213855B2 (en)	2003-02-20	2010-03-04	University Of Connecticut Health Center	Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
GB2398783A (en)	2003-02-26	2004-09-01	Antonio Lanzavecchia	A method for producing immortalised human B memory lymphocytes
WO2004075865A2 (en) *	2003-02-27	2004-09-10	3M Innovative Properties Company	Selective modulation of tlr-mediated biological activity
EP1601365A4 (en)	2003-03-04	2009-11-11	3M Innovative Properties Co	PROPHYLACTIC TREATMENT OF UV-INDUCED EPIDERMAL NEOPLASIA
DE602004022923D1 (de)	2003-03-04	2009-10-15	Intercell Ag	Streptococcus pyogenes antigene
US8426457B2 (en) *	2003-03-13	2013-04-23	Medicis Pharmaceutical Corporation	Methods of improving skin quality
US7179253B2 (en)	2003-03-13	2007-02-20	3M Innovative Properties Company	Method of tattoo removal
ES2562456T3 (es)	2003-03-24	2016-03-04	Valneva Austria Gmbh	Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
US20040192585A1 (en) *	2003-03-25	2004-09-30	3M Innovative Properties Company	Treatment for basal cell carcinoma
US7537767B2 (en)	2003-03-26	2009-05-26	Cytis Biotechnology Ag	Melan-A- carrier conjugates
EP1613775B1 (en) *	2003-03-26	2012-08-29	Multicell Immunotherapeutics, Inc.	Selected rna motifs in anti-leukemia therapy
CN100560719C (zh) *	2003-03-26	2009-11-18	赛托斯生物技术公司	Melan-a肽类似物-病毒样颗粒偶联物
US7628994B2 (en)	2003-03-31	2009-12-08	Intercell Ag	S. epidermidis antigens
US20040235770A1 (en) *	2003-04-02	2004-11-25	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
US20040265351A1 (en) *	2003-04-10	2004-12-30	Miller Richard L.	Methods and compositions for enhancing immune response
WO2004108072A2 (en) *	2003-04-10	2004-12-16	3M Innovative Properties Company	Delivery of immune response modifier compounds using metal-containing particulate support materials
SE0301109D0 (sv) *	2003-04-14	2003-04-14	Mallen Huang	Nucleotide vaccine composition
CA2522238A1 (en)	2003-04-15	2004-10-28	Intercell Ag	S. pneumoniae antigens
EP1617845A4 (en) *	2003-04-28	2006-09-20	3M Innovative Properties Co	COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS
CN101864431A (zh)	2003-05-07	2010-10-20	英特塞尔股份公司	无乳链球菌抗原ⅰ和ⅱ
CN1798563A (zh) *	2003-05-15	2006-07-05	独立行政法人科学技术振兴机构	免疫刺激剂
WO2005026375A2 (en)	2003-05-22	2005-03-24	Fraunhofer Usa, Inc.	Recombinant carrier molecule for expression, delivery and purification of target polypeptides
CA2525540A1 (en)	2003-05-30	2004-12-09	Intercell Ag	Enterococcus antigens
CA2528007C (en)	2003-06-02	2012-03-27	Chiron Corporation	Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
US7803386B2 (en)	2003-06-05	2010-09-28	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
MXPA05013922A (es) *	2003-06-20	2006-02-24	Coley Pharm Group Inc	Antagonistas de receptor tipo toll de molecula pequena.
AU2004255470B2 (en) *	2003-07-10	2010-08-19	Cytos Biotechnology Ag	Packaged virus-like particles
US20050013812A1 (en) *	2003-07-14	2005-01-20	Dow Steven W.	Vaccines using pattern recognition receptor-ligand:lipid complexes
WO2005016273A2 (en) *	2003-08-05	2005-02-24	3M Innovative Properties Company	Infection prophylaxis using immune response modifier compounds
AU2004266658A1 (en) *	2003-08-12	2005-03-03	3M Innovative Properties Company	Hydroxylamine substituted imidazo-containing compounds
US20060035242A1 (en)	2004-08-13	2006-02-16	Michelitsch Melissa D	Prion-specific peptide reagents
US20050048072A1 (en) *	2003-08-25	2005-03-03	3M Innovative Properties Company	Immunostimulatory combinations and treatments
BRPI0413998A (pt) *	2003-08-27	2006-11-07	3M Innovative Properties Co	imidazoquinolinas arilóxi e arilalquilenóxi substituìdas
US20060216333A1 (en) *	2003-09-02	2006-09-28	Miller Richard L	Methods related to the treatment of mucosal associated conditions
US20050054665A1 (en) *	2003-09-05	2005-03-10	3M Innovative Properties Company	Treatment for CD5+ B cell lymphoma
EP1670507A4 (en)	2003-09-12	2007-10-17	Antigenics Inc	VACCINE FOR THE TREATMENT AND PREVENTION OF HERPES SIMPLEX VIRUS INFECTION
CA2536139A1 (en) *	2003-09-25	2005-04-07	Coley Pharmaceutical Group, Inc.	Nucleic acid-lipophilic conjugates
AU2004277342B2 (en)	2003-10-02	2010-12-16	Glaxosmithkline Biologicals S.A.	Pertussis antigens and use thereof in vaccination
BRPI0414856A (pt) *	2003-10-03	2006-11-21	3M Innovative Properties Co	imidazoquinolinas alcóxi-substituìdas
US7544697B2 (en) *	2003-10-03	2009-06-09	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and analogs thereof
US20090075980A1 (en) *	2003-10-03	2009-03-19	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and Analogs Thereof
WO2005034979A2 (en) *	2003-10-11	2005-04-21	Inex Pharmaceuticals Corporation	Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
GEP20094767B (en) *	2003-10-30	2009-09-10	Coley Pharm Group Inc	C-class oligonucleotide analogs with enhanced immunostimulatory potency
US20050096259A1 (en) *	2003-10-31	2005-05-05	3M Innovative Properties Company	Neutrophil activation by immune response modifier compounds
US20050239733A1 (en) *	2003-10-31	2005-10-27	Coley Pharmaceutical Gmbh	Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) *	2003-11-06	2005-05-12	Coley Pharmaceutical Gmbh	Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
CA2545825A1 (en) *	2003-11-14	2005-06-02	3M Innovative Properties Company	Hydroxylamine substituted imidazo ring compounds
WO2005048933A2 (en)	2003-11-14	2005-06-02	3M Innovative Properties Company	Oxime substituted imidazo ring compounds
CA2547020C (en) *	2003-11-25	2014-03-25	3M Innovative Properties Company	1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
US20050277127A1 (en) *	2003-11-26	2005-12-15	Epitomics, Inc.	High-throughput method of DNA immunogen preparation and immunization
US20050287118A1 (en) *	2003-11-26	2005-12-29	Epitomics, Inc.	Bacterial plasmid with immunological adjuvant function and uses thereof
US8940755B2 (en) *	2003-12-02	2015-01-27	3M Innovative Properties Company	Therapeutic combinations and methods including IRM compounds
US20050226878A1 (en) *	2003-12-02	2005-10-13	3M Innovative Properties Company	Therapeutic combinations and methods including IRM compounds
EP1708745B1 (en)	2003-12-23	2012-04-18	Arbor Vita Corporation	Antibodies for oncogenic strains of hpv and methods of their use
JP4817599B2 (ja) *	2003-12-25	2011-11-16	独立行政法人科学技術振興機構	免疫活性増強剤とこれを用いた免疫活性の増強方法
WO2005066170A1 (en) *	2003-12-29	2005-07-21	3M Innovative Properties Company	Arylalkenyl and arylalkynyl substituted imidazoquinolines
JP2007517055A (ja) *	2003-12-30	2007-06-28	スリーエムイノベイティブプロパティズカンパニー	免疫応答の増強
AU2004312508A1 (en) *	2003-12-30	2005-07-21	3M Innovative Properties Company	Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
WO2005072290A2 (en) *	2004-01-23	2005-08-11	Joslin Diabetes Center	Methods of treating, reducing, or preventing autoimmune conditions
ES2541779T3 (es)	2004-02-05	2015-07-24	The Ohio State University Research Foundation	Péptidos VEGF quiméricos
US20050181035A1 (en) *	2004-02-17	2005-08-18	Dow Steven W.	Systemic immune activation method using non CpG nucleic acids
TW200533750A (en) *	2004-02-19	2005-10-16	Coley Pharm Group Inc	Immunostimulatory viral RNA oligonucleotides
WO2005090968A1 (en) *	2004-03-16	2005-09-29	Inist Inc.	Tat-based immunomodulatory compositions and methods of their discovery and use
EP1734975B1 (en)	2004-03-19	2015-06-10	Herbs Spring, LLC	Herbal therapy for the treatment of food allergy
TW200612932A (en) *	2004-03-24	2006-05-01	3M Innovative Properties Co	Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
TWI235440B (en) *	2004-03-31	2005-07-01	Advanced Semiconductor Eng	Method for making leadless semiconductor package
AU2005244260B2 (en) *	2004-04-09	2010-08-05	3M Innovative Properties Company	Methods, compositions, and preparations for delivery of immune response modifiers
MXPA06012451A (es) *	2004-04-28	2007-01-31	3M Innovative Properties Co	Composiciones y metodos para vacunacion por la mucosa.
AU2005247341B2 (en)	2004-05-06	2008-05-08	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Methods and compositions for the treatment of uveitis
CA2567597C (en)	2004-05-25	2014-03-18	Oregon Health And Science University	Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
US20050267145A1 (en) *	2004-05-28	2005-12-01	Merrill Bryon A	Treatment for lung cancer
US20080154210A1 (en)	2004-05-28	2008-06-26	Oryxe	Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds
WO2005123080A2 (en) *	2004-06-15	2005-12-29	3M Innovative Properties Company	Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US7897609B2 (en) *	2004-06-18	2011-03-01	3M Innovative Properties Company	Aryl substituted imidazonaphthyridines
US7915281B2 (en) *	2004-06-18	2011-03-29	3M Innovative Properties Company	Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
WO2006009826A1 (en) *	2004-06-18	2006-01-26	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006009832A1 (en) *	2004-06-18	2006-01-26	3M Innovative Properties Company	Substituted imidazo ring systems and methods
EP1781325A2 (en) *	2004-07-18	2007-05-09	CSL Limited	Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
DK2412728T3 (en)	2004-08-03	2015-04-07	Innate Pharma	Therapeutic compositions for cancer, that target 4Ig-B7-H3
GB0417494D0 (en)	2004-08-05	2004-09-08	Glaxosmithkline Biolog Sa	Vaccine
WO2006026470A2 (en) *	2004-08-27	2006-03-09	3M Innovative Properties Company	Hiv immunostimulatory compositions
US20090270443A1 (en) *	2004-09-02	2009-10-29	Doris Stoermer	1-amino imidazo-containing compounds and methods
JP2008513406A (ja)	2004-09-22	2008-05-01	グラクソスミスクラインバイオロジカルズソシエテアノニム	免疫原性組成物
PL1791858T3 (pl)	2004-09-24	2010-09-30	Intercell Ag	Zmodyfikowane białko kapsydowe VP1 z parwowirusa B19
JP2008000001A (ja) *	2004-09-30	2008-01-10	Osaka Univ	免疫刺激オリゴヌクレオチドおよびその医薬用途
EP1804583A4 (en) *	2004-10-08	2009-05-20	3M Innovative Properties Co	ADJUVANT FOR DNA VACCINE
EP2808384B1 (en)	2004-10-08	2017-12-06	The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services	Modulation of replicative fitness by using less frequently used synonymous codons
MY159370A (en) *	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
WO2006065549A2 (en)	2004-12-03	2006-06-22	Medical University Of Ohio	Attenuated vaccine useful for immunizations against coccidioides spp. infections
US20110070575A1 (en) *	2004-12-08	2011-03-24	Coley Pharmaceutical Group, Inc.	Immunomodulatory Compositions, Combinations and Methods
US9809824B2 (en) *	2004-12-13	2017-11-07	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
US8034938B2 (en)	2004-12-30	2011-10-11	3M Innovative Properties Company	Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
AU2005322898B2 (en)	2004-12-30	2011-11-24	3M Innovative Properties Company	Chiral fused (1,2)imidazo(4,5-c) ring compounds
HUE025749T2 (en)	2004-12-30	2016-04-28	Meda Ab	Use of Imiquimod to treat skin metastases from breast cancer
JP4993750B2 (ja)	2005-01-27	2012-08-08	チルドレンズホスピタルアンドリサーチセンターアットオークランド	髄膜炎菌に起因する疾患に対する広域防御のための、ｇｎａ１８７０を基にした小胞ワクチン
US9248127B2 (en) *	2005-02-04	2016-02-02	3M Innovative Properties Company	Aqueous gel formulations containing immune response modifiers
US7968563B2 (en)	2005-02-11	2011-06-28	3M Innovative Properties Company	Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
CN101160401A (zh) *	2005-02-24	2008-04-09	科勒制药集团公司	免疫刺激寡核苷酸
GB0504436D0 (en)	2005-03-03	2005-04-06	Glaxosmithkline Biolog Sa	Vaccine
US8101345B1 (en)	2005-03-25	2012-01-24	Isis Pharmaceuticals, Inc.	Proinflammatory nucleic acids
CN103372206A (zh)	2005-03-31	2013-10-30	葛兰素史密丝克莱恩生物有限公司	针对衣原体感染的疫苗
CA2602683A1 (en)	2005-04-01	2006-10-12	Coley Pharmaceutical Group, Inc.	Pyrazolopyridine-1,4-diamines and analogs thereof
WO2006107851A1 (en)	2005-04-01	2006-10-12	Coley Pharmaceutical Group, Inc.	1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
CA2603976A1 (en) *	2005-04-08	2006-10-19	Coley Pharmaceutical Group, Inc.	Methods for treating infectious disease exacerbated asthma
EP1865967A4 (en) *	2005-04-08	2011-02-09	Chimerix Inc	COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES
WO2006110655A2 (en)	2005-04-08	2006-10-19	Chimerix, Inc.	Compounds, compositions and methods for the treatment of poxvirus infections
AU2006241166A1 (en)	2005-04-25	2006-11-02	3M Innovative Properties Company	Immunostimulatory compositions
US20060241076A1 (en) *	2005-04-26	2006-10-26	Coley Pharmaceutical Gmbh	Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
HRP20120331T1 (hr)	2005-04-29	2012-05-31	Glaxosmithkline Biologicals Sa	Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis
US8916161B2 (en)	2005-06-14	2014-12-23	Sophiris Bio Inc.	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
JP5222134B2 (ja)	2005-06-15	2013-06-26	ザオハイオステートユニバーシティーリサーチファウンデーション	Ｈｅｒ−２ペプチド
GB0513421D0 (en)	2005-06-30	2005-08-03	Glaxosmithkline Biolog Sa	Vaccines
SI2179737T1 (sl)	2005-07-01	2014-02-28	Index Pharmaceuticals Ab	Modulacija reakcije na stereoide
CA2612162C (en)	2005-07-01	2016-05-17	Index Pharmaceuticals Ab	Use of oligonucleotides in steroid refractory or steroid dependent inflammatory conditions
EP1904530A2 (en) *	2005-07-07	2008-04-02	Coley Pharmaceutical Group, Inc.	Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
US20080206276A1 (en)	2005-07-08	2008-08-28	Michael Otto	Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections
CN101262883A (zh)	2005-07-11	2008-09-10	环球免疫公司	引发针对靶向的疗法的逃逸突变体的免疫应答的组合物和方法
CN101378781B (zh)	2005-08-03	2013-08-07	美国弗劳恩霍夫股份有限公司	制造免疫球蛋白的组合物和方法
US20100130425A1 (en)	2005-09-09	2010-05-27	Oregon Health & Science University	Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
KR20080047463A (ko) *	2005-09-16	2008-05-28	콜리 파마슈티칼 게엠베하	뉴클레오티드 변형에 의한 짧은 간섭 리보핵산(ｓｉｒｎａ)의 면역자극 특성의 조절
JP2010503608A (ja) *	2005-09-16	2010-02-04	コーリーファーマシューティカルゲーエムベーハー	ホスホジエステルバックボーンを有する免疫刺激性一本鎖リボ核酸
WO2007041190A2 (en) *	2005-09-30	2007-04-12	The University Of Iowa Research Foundation	Polymer-based delivery system for immunotherapy of cancer
AU2006306805A1 (en)	2005-10-28	2007-05-03	Index Pharmaceuticals Ab	Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
BRPI0622298A8 (pt) *	2005-11-25	2016-04-05	Coley Pharm Gmbh	Oligorribonucleotídeo para estimular a produção de uma citocina pró-inflamatória, uso do mesmo e composição contendo tal oligorribonucleotídeo
CA2632630C (en)	2005-12-13	2016-12-06	President And Fellows Of Harvard College	Scaffolds for cell transplantation
JP5484732B2 (ja)	2005-12-14	2014-05-07	サイトスバイオテクノロジーアーゲー	過敏症の治療のための免疫賦活性核酸パッケージ粒子
DK2384765T3 (en)	2005-12-22	2017-01-09	Glaxosmithkline Biologicals Sa	Vaccine against Streptococcus pneumoniae.
GB0607088D0 (en)	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
EP1981905B1 (en)	2006-01-16	2016-08-31	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES	Chlamydia vaccine
JP5275814B2 (ja)	2006-01-17	2013-08-28	フオルスレン，アルネ	新規表面露出ヘモフィルス・インフルエンザ（ＨＡＥＭＯＰＨＩＬＵＳＩＮＦＬＵＥＮＺＡＥ）タンパク質（タンパク質Ｅ；ｐＥ）
BRPI0707733B1 (pt)	2006-02-13	2019-12-31	Ibio, Inc.	antígeno isolado, composição de vacina, uso da referida composição e método para produção de uma proteína de antígeno
CA2642152C (en)	2006-02-15	2016-11-01	Coley Pharmaceutical Gmbh	Compositions and methods for oligonucleotide formulations
US8951528B2 (en) *	2006-02-22	2015-02-10	3M Innovative Properties Company	Immune response modifier conjugates
EP2441493B1 (en)	2006-03-14	2014-05-07	Oregon Health and Science University	Methods for producing an immune response to tuberculosis
MY148405A (en)	2006-03-30	2013-04-30	Glaxosmithkline Biolog Sa	Immunogenic composition
US20100016250A1 (en)	2006-04-14	2010-01-21	Kyowa Hakko Kirin Co., Ltd.	Toll-like receptor 9 agonists
CN101460620B (zh)	2006-05-31	2012-02-15	东丽株式会社	免疫刺激寡核苷酸及其药物用途
EA200802242A1 (ru)	2006-06-02	2009-08-28	Глаксосмитклайн Байолоджикалс С.А.	Способ определения того, будет или не будет пациент респондером на иммунотерапию
KR100906970B1 (ko)	2006-06-03	2009-07-10	주식회사 바이오씨에스	피부 면역질환에 대한 ＣｐＧ 올리고데옥시뉴클레오티드의치료학적 용도
WO2007143582A2 (en) *	2006-06-05	2007-12-13	Baylor College Of Medicine	Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
EP2032161B1 (en)	2006-06-12	2012-07-11	GlaxoSmithKline Biologicals S.A.	L3v los vaccines
KR101552227B1 (ko)	2006-06-12	2015-09-10	사이토스 바이오테크놀로지 아게	올리고뉴클레오티드를 ｒｎａ 박테리오파지의 바이러스-유사 입자로 패키징하는 방법
CN101490083A (zh)	2006-07-07	2009-07-22	英特塞尔股份公司	小化脓性链球菌抗原及其用途
WO2008094183A2 (en) *	2006-07-11	2008-08-07	University Of Connecticut	Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
US8153116B2 (en)	2006-07-11	2012-04-10	University Of Connecticut	Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
WO2008008432A2 (en) *	2006-07-12	2008-01-17	Coley Pharmaceutical Group, Inc.	Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
DE102006035618A1 (de) *	2006-07-31	2008-02-07	Curevac Gmbh	Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
AU2007280690C1 (en)	2006-07-31	2012-08-23	Curevac Gmbh	Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
PT2097102E (pt)	2006-09-07	2012-08-03	Glaxosmithkline Biolog Sa	Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus
AU2007295927A1 (en)	2006-09-15	2008-03-20	Intercell Ag	Borrelia antigens
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
PT2484375T (pt)	2006-09-26	2018-07-09	Infectious Disease Res Inst	Composição para vacina contendo adjuvante sintético
NZ575437A (en)	2006-09-27	2012-02-24	Coley Pharm Gmbh	Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
MX2009004510A (es) *	2006-10-26	2009-05-12	Coley Pharm Gmbh	Oligorribonucleotidos y sus usos.
DK3564674T3 (da) *	2006-11-01	2021-10-18	Ventana Med Syst Inc	Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til fremstilling og anvendelse deraf
WO2008057529A2 (en) *	2006-11-06	2008-05-15	Coley Pharmaceutical Group, Inc.	Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp)
CN104857512A (zh)	2006-11-09	2015-08-26	戴纳瓦克斯技术公司	使用免疫刺激性寡核苷酸进行长期的疾病修饰
EP1923069A1 (en)	2006-11-20	2008-05-21	Intercell AG	Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
US20080149123A1 (en)	2006-12-22	2008-06-26	Mckay William D	Particulate material dispensing hairbrush with combination bristles
EP2266591A3 (en)	2007-01-12	2012-08-08	Intercell AG	Protective proteins of S. agalactiae, combinations thereof and methods of using the same
JP5596980B2 (ja)	2007-02-28	2014-10-01	アメリカ合衆国	ブラキュリポリペプチドおよび使用方法
AU2008223951B2 (en)	2007-03-02	2014-03-27	Glaxosmithkline Biologicals S.A.	Novel method and compositions
CN101687900A (zh) *	2007-03-07	2010-03-31	恩文塔生物制药公司	双链锁核酸组合物
MX2009010066A (es)	2007-03-19	2009-10-12	Globeimmune Inc	Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer.
DK2136836T3 (en)	2007-04-04	2017-04-10	Infectious Disease Res Inst	Immunogenic compositions with mycobacterium tuberculosis polypeptides and fusions thereof
AR066405A1 (es)	2007-04-20	2009-08-19	Glaxosmithkline Biolog Sa	Vacuna
US8778348B2 (en)	2007-04-28	2014-07-15	Ibio Inc.	Trypanosoma antigens, vaccine compositions, and related methods
JP2010525035A (ja)	2007-05-02	2010-07-22	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
CA2685805A1 (en)	2007-05-02	2008-11-13	Intercell Ag	Klebsiella antigens
WO2008136748A1 (en) *	2007-05-04	2008-11-13	Index Pharmaceuticals Ab	Tumour growth inhibitory compounds and methods of their use
BRPI0811621A2 (pt) *	2007-05-17	2014-10-21	Coley Pharm Group Inc	Oligonucleotídeos de classe a com potência imunoestimuladora, composição contendo os mesmos e uso da referida composição
CA2687535C (en) *	2007-05-18	2017-08-22	Coley Pharmaceutical Gmbh	Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity
JP2010528285A (ja)	2007-05-23	2010-08-19	ベンタナ・メデイカル・システムズ・インコーポレーテツド	免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体
SI2148697T1 (sl)	2007-05-24	2013-01-31	Glaxosmithkline Biologicals S.A.	Liofilizirani sestavek, ki vsebuje CpG in WT-1
EP2012122A1 (en)	2007-07-06	2009-01-07	Medigene AG	Mutated parvovirus structural proteins as vaccines
EP2158211B1 (en)	2007-05-31	2016-08-10	Medigene AG	Mutated structural protein of a parvovirus
CA2690271A1 (en)	2007-06-18	2008-12-24	Intercell Ag	Chlamydia antigens
PL2167121T3 (pl)	2007-06-26	2016-01-29	Glaxosmithkline Biologicals Sa	Szczepionka zawierająca koniugaty polisacharydu otoczkowego streptococcus pneumoniae
EP3061462B1 (en)	2007-07-02	2019-02-27	Etubics Corporation	Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
WO2009009759A2 (en)	2007-07-11	2009-01-15	Fraunhofer Usa, Inc.	Yersinia pestis antigens, vaccine compositions, and related methods
ES2539818T3 (es)	2007-08-02	2015-07-06	Biondvax Pharmaceuticals Ltd.	Vacunas contra la gripe multiepitópicas multiméricas
US20100260791A1 (en)	2007-08-03	2010-10-14	President And Fellows Of Harvard	Chlamydia antigens
US7879812B2 (en)	2007-08-06	2011-02-01	University Of Iowa Research Foundation	Immunomodulatory oligonucleotides and methods of use therefor
JP5508266B2 (ja)	2007-08-13	2014-05-28	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
EP2187961A2 (en) *	2007-08-21	2010-05-26	Dynavax Technologies Corporation	Composition and methods of making and using influenza proteins
JP2010536907A (ja)	2007-08-31	2010-12-02	ニューリミューンセラピューティクスエイジー	患者にアミロイドーシスおよびタンパク質凝集性障害における特異的免疫応答をもたらす方法
WO2009030254A1 (en)	2007-09-04	2009-03-12	Curevac Gmbh	Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009037441A1 (en)	2007-09-17	2009-03-26	Oncomethylome Sciences Sa	Improved methylation detection
KR20100068422A (ko)	2007-10-09	2010-06-23	콜리 파마슈티칼 게엠베하	변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체
DK2224954T3 (en)	2007-11-07	2014-03-03	Celldex Therapeutics Inc	Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
CA2960659C (en)	2007-11-09	2021-07-13	The Salk Institute For Biological Studies	Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
CA2744739A1 (en)	2007-12-03	2009-06-11	President And Fellows Of Harvard College	Chlamydia antigens
ES2664753T3 (es)	2007-12-07	2018-04-23	Glaxosmithkline Biologicals Sa	Composiciones de inducción de respuestas inmunes
EP4206231A1 (en)	2007-12-24	2023-07-05	ID Biomedical Corporation of Quebec	Recombinant rsv antigens
CN101977610B (zh) *	2008-01-25	2012-05-16	奇默里克斯公司	治疗病毒感染的方法
SI2176408T1 (sl)	2008-01-31	2015-05-29	Curevac Gmbh	Nukleinske kisline, ki vsebujejo formulo (NuGiXmGnNv)a in njeni derivati kot imunostimulirajoča sredstva/adjuvanse
US10328133B2 (en)	2008-02-13	2019-06-25	President And Fellows Of Harvard College	Continuous cell programming devices
US10383887B2 (en)	2008-02-20	2019-08-20	New York University	Preventing and treating amyloid-beta deposition by stimulation of innate immunity
CA2717870A1 (en)	2008-03-10	2009-09-17	Children's Hospital & Research Center At Oakland	Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
AU2009226949A1 (en)	2008-03-17	2009-09-24	Intercell Ag	Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
WO2009129502A2 (en)	2008-04-18	2009-10-22	The General Hospital Corporation	Immunotherapies employing self-assembling vaccines
CA2724418A1 (en) *	2008-05-15	2009-11-19	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
EP2278979A4 (en)	2008-05-21	2012-09-26	Us Gov Health & Human Serv	PROCESS FOR TREATING PNEUMOCONIOSIS WITH OLIGODEOXYNUCLEOTIDES
AU2009248810B2 (en)	2008-05-23	2013-12-05	The Regents Of The University Of Michigan	Nanoemulsion vaccines
EP2300799B1 (en)	2008-06-05	2015-11-25	Ventana Medical Systems, Inc.	Method for histochemical processessing and use of a composition for histochemical processing
TWI351288B (en) *	2008-07-04	2011-11-01	Univ Nat Pingtung Sci & Tech	Cpg dna adjuvant in avian vaccines
CA2733356C (en)	2008-08-01	2016-06-07	Gamma Vaccines Pty Limited	Influenza vaccines
EP2353008A2 (en)	2008-09-22	2011-08-10	Oregon Health and Science University	Methods for detecting a mycobacterium tuberculosis infection
US8962026B2 (en)	2008-09-26	2015-02-24	The Regents Of The University Of Michigan	Nanoemulsion therapeutic compositions and methods of using the same
WO2010037046A1 (en)	2008-09-28	2010-04-01	Fraunhofer Usa, Inc.	Humanized neuraminidase antibody and methods of use thereof
WO2010037408A1 (en)	2008-09-30	2010-04-08	Curevac Gmbh	Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
NZ591925A (en)	2008-10-16	2012-09-28	Internat Vaccine Inst	Adjuvant composition comprising a host defense peptide, an immunostimulatory sequence and a polyanionic polymer
US9732324B2 (en)	2008-10-23	2017-08-15	Cornell University	Anti-viral method
WO2010048731A1 (en) *	2008-10-31	2010-05-06	Christopher John Ong	Aminoacyl trna-synthetase inhibitors as broad-spectrum immunosuppressive agents
WO2010057197A1 (en)	2008-11-17	2010-05-20	The Regents Of The University Of Michigan	Cancer vaccine compositions and methods of using the same
US9283184B2 (en)	2008-11-24	2016-03-15	Massachusetts Institute Of Technology	Methods and compositions for localized agent delivery
CA2744987C (en)	2008-12-02	2018-01-16	Chiralgen, Ltd.	Method for the synthesis of phosphorus atom modified nucleic acids
US20110236470A1 (en)	2008-12-03	2011-09-29	Yaffa Mizrachi Nebenzahl	GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
CN102325790A (zh)	2008-12-03	2012-01-18	西马生物医学计划公司	应用酚可溶性调控蛋白研制疫苗
US8552165B2 (en) *	2008-12-09	2013-10-08	Heather Davis	Immunostimulatory oligonucleotides
MX337723B (es)	2008-12-09	2016-03-15	Pfizer Vaccines Llc	Vacuna de peptido ch3 de ige.
EP2376107B1 (en)	2008-12-09	2014-05-21	Coley Pharmaceutical Group, Inc.	Immunostimulatory oligonucleotides
EP2384120B1 (en)	2009-01-05	2019-12-11	Epitogenesis Inc.	Adjuvant compositions and methods of use
WO2010084100A1 (en)	2009-01-20	2010-07-29	Transgene Sa	Soluble icam-1 as biomarker for prediction of therapeutic response
US20100234283A1 (en)	2009-02-04	2010-09-16	The Ohio State University Research Foundation	Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
US20130243779A1 (en)	2009-02-05	2013-09-19	Intercell Ag	Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (en)	2009-02-13	2012-01-18	Intercell AG	Nontypable haemophilus influenzae antigens
WO2010099472A2 (en)	2009-02-27	2010-09-02	The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services	Spanx-b polypeptides and their use
BRPI1009873A2 (pt)	2009-03-17	2016-03-08	Glaxosmithkline Biolog Sa	detecção aperfeiçoada de expressão gênica
DK2411043T3 (da)	2009-03-23	2013-10-21	Pin Pharma Inc	Behandling af cancer med immunostimulatorisk hiv tat derivat-polypeptider
ES2555858T3 (es)	2009-03-24	2016-01-11	Transgene Sa	Biomarcador para el control de pacientes
EP2413953B1 (en)	2009-04-03	2017-11-08	Agenus Inc.	Methods for preparing and using multichaperone-antigen complexes
HRP20140262T1 (hr)	2009-04-17	2014-04-25	Transgene Sa	Biomarker za praä†enje pacijenata
US20110223201A1 (en) *	2009-04-21	2011-09-15	Selecta Biosciences, Inc.	Immunonanotherapeutics Providing a Th1-Biased Response
WO2010125480A1 (en)	2009-04-30	2010-11-04	Coley Pharmaceutical Group, Inc.	Pneumococcal vaccine and uses thereof
WO2010138193A2 (en)	2009-05-27	2010-12-02	Selecta Biosciences, Inc.	Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
SG176220A1 (en)	2009-05-27	2011-12-29	Glaxosmithkline Biolog Sa	Casb7439 constructs
HRP20161585T1 (hr)	2009-06-05	2016-12-30	Infectious Disease Research Institute	Sintetski glukopiranozilni lipidi kao adjuvansi i cjepivni pripravci koji ih sadrže
CN102596243B (zh)	2009-06-16	2015-10-21	密执安大学评议会	纳米乳剂疫苗
WO2010149743A2 (en)	2009-06-24	2010-12-29	Id Biomedical Corporation Of Quebec	Vaccine
ES2583257T3 (es)	2009-06-24	2016-09-20	Glaxosmithkline Biologicals S.A.	Antígenos recombinantes del VSR
CA2767253A1 (en)	2009-07-06	2011-01-13	Ontorii, Inc.	Novel nucleic acid prodrugs and methods of use thereof
DK2452194T3 (en)	2009-07-10	2015-11-30	Transgene Sa	Biomarker PATIENT SELECTION AND RELATED PRACTICES
ES2563730T3 (es)	2009-07-15	2016-03-16	Glaxosmithkline Biologicals S.A.	Composiciones de proteína RSV F y procedimientos de fabricación de las mismas
US8614200B2 (en)	2009-07-21	2013-12-24	Chimerix, Inc.	Compounds, compositions and methods for treating ocular conditions
RU2518291C2 (ru)	2009-07-30	2014-06-10	Пфайзер Вэксинс ЭлЭлСи	Антигенные tau-пептиды и их применения
US20110033515A1 (en) *	2009-08-04	2011-02-10	Rst Implanted Cell Technology	Tissue contacting material
GB0913681D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
GB0913680D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
US20120190634A1 (en)	2009-08-26	2012-07-26	Rna Inc.	Lipoteichoic acid-derived glycolipids, and compositions comprising same
WO2011026111A1 (en)	2009-08-31	2011-03-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Oral delivery of a vaccine to the large intestine to induce mucosal immunity
MY163512A (en)	2009-09-03	2017-09-15	Pfizer Vaccines Llc	Pcsk9 vaccine
US20110053829A1 (en)	2009-09-03	2011-03-03	Curevac Gmbh	Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
CN102573886A (zh) *	2009-09-17	2012-07-11	相互制药公司	用抗病毒剂治疗哮喘的方法
GB0917457D0 (en)	2009-10-06	2009-11-18	Glaxosmithkline Biolog Sa	Method
CA2776144C (en)	2009-09-29	2020-10-27	Fraunhofer Usa, Inc.	Influenza hemagglutinin antibodies, compositions, and related methods
CN102782138A (zh)	2009-10-07	2012-11-14	Uvic工业合伙公司	包含热敏性转基因的疫苗
EP2319871A1 (en)	2009-11-05	2011-05-11	Sanofi-aventis	Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP2308896A1 (en)	2009-10-09	2011-04-13	Sanofi-aventis	Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
BR112012007821A2 (pt)	2009-10-09	2017-05-30	Sanofi Sa	polipeptídeos para ligação ao "receptor de produtos finais de glicação avançada" bem como composições e métodos envolvendo os mesmos
WO2011047340A1 (en)	2009-10-16	2011-04-21	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
GB0919117D0 (en)	2009-10-30	2009-12-16	Glaxosmithkline Biolog Sa	Process
EP2501397B1 (en)	2009-11-20	2017-10-04	Oregon Health and Science University	Methods for producing an immune response to tuberculosis
WO2011067758A2 (en)	2009-12-02	2011-06-09	Protea Vaccine Technologies Ltd.	Immunogenic fragments and multimers from streptococcus pneumoniae proteins
NZ600978A (en)	2009-12-22	2014-08-29	Celldex Therapeutics Inc	Vaccine compositions
FR2954703B1 (fr)	2009-12-28	2013-12-13	Chu Nantes	Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes
DK2534150T3 (en)	2010-02-12	2017-06-12	Chimerix Inc	METHODS OF TREATING VIRUS INFECTION
WO2011101332A1 (en)	2010-02-16	2011-08-25	Proyecto De Biomedicina Cima, S.L.	Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2011109422A2 (en)	2010-03-02	2011-09-09	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Compositions and methods for the treatment of cancer
CA2792258A1 (en)	2010-03-05	2011-09-09	President And Fellows Of Harvard College	Induced dendritic cell compositions and uses thereof
GB201003924D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Immunogenic composition
GB201003920D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Method of treatment
BR112012022669A2 (pt)	2010-03-10	2017-02-14	Glaxosmithkline Biologicals Sa	composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.
WO2011112599A2 (en)	2010-03-12	2011-09-15	The United States Of America, As Represented By The Secretary. Department Of Health & Human Services	Immunogenic pote peptides and methods of use
US20110229556A1 (en) *	2010-03-19	2011-09-22	Massachusetts Institute Of Technology	Lipid-coated polymer particles for immune stimulation
US9149432B2 (en)	2010-03-19	2015-10-06	Massachusetts Institute Of Technology	Lipid vesicle compositions and methods of use
MX2012010810A (es) *	2010-03-19	2013-02-07	Massachusetts Inst Technology	Composiciones de vesícula de lípido y métodos de uso.
GB201005005D0 (en)	2010-03-25	2010-05-12	Angeletti P Ist Richerche Bio	New vaccine
TR201802933T4 (tr)	2010-03-30	2018-03-21	Childrens Hospital & Res Center At Oakland	Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
NZ602892A (en)	2010-04-13	2014-08-29	Celldex Therapeutics Inc	Antibodies that bind human cd27 and uses thereof
WO2011139709A2 (en)	2010-04-26	2011-11-10	Chimerix, Inc.	Methods of treating retroviral infections and related dosage regimes
HUE049725T2 (hu)	2010-05-14	2020-10-28	Univ Oregon Health & Science	Hepatitisz B vírusból izolált heterológ antigént kódoló rekombináns HCMV és RhCMV vektorok és alkalmazásuk
WO2011150264A2 (en)	2010-05-26	2011-12-01	Selecta Biosciences, Inc.	Synthetic nanocarrier combination vaccines
AU2011259718B2 (en)	2010-05-28	2016-03-03	Zoetis Belgium S.A.	Vaccines comprising cholesterol and CpG as sole adjuvant - carrier molecules
WO2011154878A1 (en)	2010-06-07	2011-12-15	Pfizer Vaccines Llc	Ige ch3 peptide vaccine
US8658603B2 (en)	2010-06-16	2014-02-25	The Regents Of The University Of Michigan	Compositions and methods for inducing an immune response
CN107648604A (zh)	2010-07-30	2018-02-02	库瑞瓦格股份公司	聚合物载体运载物复合物及聚合物载体的用途
JP6121421B2 (ja)	2010-09-03	2017-04-26	バルネバオーストリアジーエムビーエイチ	Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
AR082925A1 (es)	2010-09-08	2013-01-16	Medigene Ag	Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados
GB201015132D0 (en)	2010-09-10	2010-10-27	Univ Bristol	Vaccine composition
CA2811103C (en)	2010-09-14	2020-01-14	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Computationally optimized broadly reactive antigens for influenza
WO2012039448A1 (ja)	2010-09-24	2012-03-29	株式会社キラルジェン	不斉補助基
US9168292B2 (en)	2010-09-27	2015-10-27	Crucell Holland B.V.	Heterologous prime boost vaccination regimen against malaria
ES2773858T3 (es)	2010-10-06	2020-07-15	Harvard College	Hidrogeles formadores de poros inyectables para terapias celulares basadas en materiales
US20130345079A1 (en)	2010-10-27	2013-12-26	Infectious Disease Research Institute	Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
WO2012061717A1 (en)	2010-11-05	2012-05-10	Selecta Biosciences, Inc.	Modified nicotinic compounds and related methods
ES2859673T3 (es)	2010-11-08	2021-10-04	Infectious Disease Res Inst	Vacunas que comprenden polipéptidos de nucleósido hidrolasa no específica y esterol 24-c-metiltransferasa (SMT) para el tratamiento y el diagnóstico de la leishmaniasis
AU2011343367B2 (en)	2010-12-14	2015-05-21	Glaxosmithkline Biologicals S.A.	Mycobacterium antigenic composition
EP2667891B1 (en)	2011-01-27	2021-10-06	Gamma Vaccines Pty Limited	Combination vaccines
CA2828068C (en)	2011-02-22	2019-03-19	Biondvax Pharmaceuticals Ltd.	Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US20140004142A1 (en)	2011-03-02	2014-01-02	Pfizer Inc.	Pcsk9 vaccine
EP2505640A1 (en)	2011-03-29	2012-10-03	Neo Virnatech, S.L.	Vaccine compositions for birnavirus-borne diseases
GB201106357D0 (en)	2011-04-14	2011-06-01	Pessi Antonello	Composition and uses thereof
EP3632463A1 (en)	2011-04-08	2020-04-08	Immune Design Corp.	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
TW201302779A (zh)	2011-04-13	2013-01-16	Glaxosmithkline Biolog Sa	融合蛋白質及組合疫苗
US20120288515A1 (en)	2011-04-27	2012-11-15	Immune Design Corp.	Synthetic long peptide (slp)-based vaccines
US9675561B2 (en)	2011-04-28	2017-06-13	President And Fellows Of Harvard College	Injectable cryogel vaccine devices and methods of use thereof
SI2707385T1 (en)	2011-05-13	2018-01-31	Glaxosmithkline Biologicals Sa	Pregnant RSV F antigens
FR2975600B1 (fr)	2011-05-24	2013-07-05	Assist Publ Hopitaux De Paris	Agents pour le traitement de tumeurs
EP2713737B1 (en)	2011-06-01	2016-04-20	Janus Biotherapeutics, Inc.	Novel immune system modulators
US9359361B2 (en)	2011-06-01	2016-06-07	Janus Biotherapeutics, Inc.	Immune system modulators
US9475804B2 (en)	2011-06-03	2016-10-25	3M Innovative Properties Company	Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
EP2718292B1 (en)	2011-06-03	2018-03-14	3M Innovative Properties Company	Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
US20130156803A1 (en)	2011-06-04	2013-06-20	Rochester General Hospital Research Institute	Compositions and methods related to p6
BR112013031564B1 (pt)	2011-06-07	2021-11-03	Ibio, Inc	Métodos para geração e expressão de um polipeptídio e sistema de expressão
CA2838981C (en)	2011-06-17	2020-09-08	University Of Tennessee Research Foundation	Group a streptococcus multivalent vaccine
AU2012273039B2 (en)	2011-06-20	2016-12-01	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	Computationally optimized broadly reactive antigens for H1N1 influenza
CN103608030A (zh)	2011-06-21	2014-02-26	昂科发克特公司	用于治疗和诊断癌症的组合物和方法
WO2013007703A1 (en) *	2011-07-08	2013-01-17	Universität Zürich	CLASS A CpG OLIGONUCLEOTIDES FOR PREVENTION OF VIRAL INFECTION IN CATS
WO2013012758A1 (en)	2011-07-19	2013-01-24	Ontorii, Inc.	Methods for the synthesis of functionalized nucleic acids
US20130023736A1 (en)	2011-07-21	2013-01-24	Stanley Dale Harpstead	Systems for drug delivery and monitoring
CA2843274A1 (en)	2011-07-29	2013-02-07	Selecta Biosciences, Inc.	Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
GB201114919D0 (en)	2011-08-30	2011-10-12	Glaxosmithkline Biolog Sa	Method
WO2013039792A1 (en)	2011-09-12	2013-03-21	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Immunogens based on an hiv-1 gp120 v1v2 epitope
PT2758432T (pt)	2011-09-16	2019-06-14	Ucb Biopharma Sprl	Anticorpos neutralizantes contra as exotoxinas principais tcda e tcdb de clostridium difficile
PT2572725E (pt)	2011-09-21	2015-10-20	Univ Heidelberg Ruprecht Karls	Péptidos frameshift específicos de ims para a prevenção e tratamento do cancro¿
WO2013049535A2 (en)	2011-09-30	2013-04-04	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Influenza vaccine
AU2012318694B2 (en)	2011-10-04	2016-12-22	Janus Biotherapeutics, Inc.	Novel imidazole quinoline-based immune system modulators
EP3269728B1 (en)	2011-10-20	2020-12-16	The Government of The United States of America as represented by The Secretary, Department of Health and Human Services	Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
US20130122038A1 (en)	2011-11-14	2013-05-16	The United States Of America As Represented By The Secretary Of The Department	Heterologous prime-boost immunization using measles virus-based vaccines
EP2596806A1 (en)	2011-11-25	2013-05-29	Index Pharmaceuticals AB	Method for prevention of colectomy
AP2014007804A0 (en)	2012-01-16	2014-07-31	Elizabeth Mckenna	Compositions and methods for the treatment of hepatic diseases and disorders.
US12268718B2 (en)	2012-01-16	2025-04-08	Labyrinth Holdings Llc	Control of cellular redox levels
WO2013113326A1 (en)	2012-01-31	2013-08-08	Curevac Gmbh	Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
BR112014018884A2 (pt)	2012-02-07	2017-07-04	Univ Pittsburgh Commonwealth Sys Higher Education	antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b
DK2811981T3 (da)	2012-02-07	2019-06-11	Infectious Disease Res Inst	Forbedrede adjuvansformuleringer, der omfatter tlr4-agonister, og fremgangsmåder til anvendelse heraf
MX359071B (es)	2012-02-13	2018-09-13	Univ Pittsburgh Commonwealth Sys Higher Education	Antígenos ampliamente reactivos computacionalmente optimizados para influenza h5n1 humana y aviar.
CA2866185C (en)	2012-03-23	2021-04-06	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pathogenic phlebovirus isolates and compositions and methods of use
EP3492095A1 (en)	2012-04-01	2019-06-05	Technion Research & Development Foundation Limited	Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
CN104244929B (zh)	2012-04-16	2017-04-05	哈佛学院董事会	用于调节免疫反应的介孔二氧化硅组合物
WO2013163176A1 (en)	2012-04-23	2013-10-31	Allertein Therapeutics, Llc	Nanoparticles for treatment of allergy
NZ701324A (en)	2012-05-04	2016-09-30	Pfizer	Prostate-associated antigens and vaccine-based immunotherapy regimens
US9555099B2 (en)	2012-05-16	2017-01-31	Immune Design Corp.	Vaccines for HSV-2
EP2852405B1 (en)	2012-05-23	2019-03-13	The United States of America, as represented by The Secretary, Department of Health and Human Services	Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof
EP2666785A1 (en)	2012-05-23	2013-11-27	Affiris AG	Complement component C5a-based vaccine
US9427476B2 (en)	2012-05-24	2016-08-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Multivalent meningococcal conjugates and methods for preparing conjugates
US9687542B2 (en)	2012-06-19	2017-06-27	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Rift valley fever virus replicon particles and use thereof
KR102712879B1 (ko)	2012-07-13	2024-10-04	웨이브 라이프 사이언시스 리미티드	키랄 제어
CN104684923B (zh)	2012-07-13	2018-09-28	株式会社新日本科学	手性核酸佐剂
JP6268157B2 (ja)	2012-07-13	2018-01-24	株式会社ＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＪａｐａｎ	不斉補助基
MX385774B (es)	2012-08-03	2025-03-18	Infectious Disease Res Inst	Composiciones para usarse en el tratamiento de una infección activa por mycobacterium tuberculosis.
AU2013301312A1 (en)	2012-08-06	2015-03-19	Glaxosmithkline Biologicals S.A.	Method for eliciting in infants an immune response against RSV and B. pertussis
US20140037680A1 (en)	2012-08-06	2014-02-06	Glaxosmithkline Biologicals, S.A.	Novel method
WO2014031178A1 (en)	2012-08-24	2014-02-27	Etubics Corporation	Replication defective adenovirus vector in vaccination
EP2703483A1 (en)	2012-08-29	2014-03-05	Affiris AG	PCSK9 peptide vaccine
WO2014037124A1 (en)	2012-09-04	2014-03-13	Bavarian Nordic A/S	Methods and compositions for enhancing vaccine immune responses
WO2014043189A1 (en)	2012-09-14	2014-03-20	The Regents Of The University Of Colorado, A Body Corporate	Conditionally replication deficient herpes viruses and use thereof in vaccines
EP2895191B1 (en)	2012-09-14	2019-06-05	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Brachyury protein, adenoviral vectors encoding brachyury protein, and their use
WO2014043535A1 (en)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions for the treatment of cancer
WO2014047588A1 (en)	2012-09-21	2014-03-27	Elizabeth Mckenna	Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof
WO2014066663A1 (en)	2012-10-24	2014-05-01	Platelet Targeted Therapeutics, Llc	Platelet targeted treatment
BR112015013737B1 (pt)	2012-12-13	2021-07-27	Ruprecht-Karls-Universitãt Heidelberg	Peptídeos com alteração do quadro de leitura msiespecífico (fsp) para a prevenção e tratamento do câncer
HUE051988T2 (hu)	2013-01-07	2021-04-28	Univ Pennsylvania	Készítmények és eljárások bõr T-sejt lymphoma kezelésére
JP2016507520A (ja)	2013-01-23	2016-03-10	ザボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティー	安定化されたｂ型肝炎コアポリペプチド
WO2014160463A1 (en)	2013-03-13	2014-10-02	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Prefusion rsv f proteins and their use
WO2014140166A2 (en)	2013-03-15	2014-09-18	Glaxosmithkline Biologicals S.A.	Vaccine
ES2728865T3 (es)	2013-03-28	2019-10-29	Infectious Disease Res Inst	Vacunas que comprenden polipéptidos de Leishmania para el tratamiento y el diagnóstico de la leishmaniasis
KR102233251B1 (ko)	2013-04-03	2021-03-26	엔-폴드 엘엘씨	신규 나노입자 조성물
AU2014253791B2 (en)	2013-04-18	2019-05-02	Immune Design Corp.	GLA monotherapy for use in cancer treatment
CN105392882A (zh)	2013-04-19	2016-03-09	加利福尼亚大学董事会	孤星病毒
WO2015132619A1 (en)	2013-05-15	2015-09-11	The Governors Of The University Of Alberta	E1e2 hcv vaccines and methods of use
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en)	2013-06-05	2013-07-17	Glaxosmithkline Biolog Sa	Immunogenic composition for use in therapy
WO2014201245A1 (en)	2013-06-12	2014-12-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
WO2015013673A1 (en)	2013-07-25	2015-01-29	Aurasense Therapeutics, Llc	Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US9919029B2 (en)	2013-07-26	2018-03-20	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and pharmaceutical compositions for the treatment of bacterial infections
US20160193322A1 (en)	2013-08-05	2016-07-07	Glaxosmithkline Biologicals S.A.	Combination immunogenic compositions
WO2015024668A2 (en)	2013-08-21	2015-02-26	Curevac Gmbh	Respiratory syncytial virus (rsv) vaccine
EP4043036A1 (en)	2013-09-27	2022-08-17	Massachusetts Institute of Technology	Carrier-free biologically-active protein nanostructures
ES2957209T3 (es)	2013-09-30	2024-01-15	Triad Nat Security Llc	Polipéptidos inmunogénicos mosaicos del VIH de región conservada
AU2014329393B2 (en)	2013-10-04	2020-04-30	Pin Pharma, Inc.	Immunostimulatory HIV Tat derivative polypeptides for use in cancer treatment
CA2928700C (en)	2013-11-01	2019-01-15	University Of Oslo	Albumin variants and uses thereof
MY196581A (en)	2013-11-01	2023-04-19	Pfizer	Vectors for Expression of Prostate-Associated Antigens
US10357554B2 (en)	2013-11-11	2019-07-23	The United States Of America, As Represented By The Secretary Of The Army	AMA-1 epitopes, antibodies, compositions, and methods of making and using the same
CA2929126C (en)	2013-11-13	2020-01-07	University Of Oslo	Outer membrane vesicles and uses thereof
WO2015071763A2 (en)	2013-11-15	2015-05-21	Oslo Universitetssykehus Hf	Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015077442A2 (en)	2013-11-20	2015-05-28	La Jolla Institute For Allergy And Immunology	Grass pollen immunogens and methods and uses for immune response modulation
US20160287696A1 (en)	2013-11-20	2016-10-06	La Jolla Institute For Allergy And Immunology	Pan pollen immunogens and methods and uses for immune response modulation
ES2895977T3 (es)	2013-11-28	2022-02-23	Bavarian Nordic As	Composiciones y métodos de inducción de una respuesta inmunitaria mejorada usando vectores de poxvirus
EP3079716B1 (en)	2013-12-13	2019-05-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Multi-epitope tarp peptide vaccine and uses thereof
WO2015092710A1 (en)	2013-12-19	2015-06-25	Glaxosmithkline Biologicals, S.A.	Contralateral co-administration of vaccines
IL310015B1 (en)	2013-12-31	2025-10-01	Access To Advanced Health Inst	Single vial formulation
JPWO2015108046A1 (ja) *	2014-01-15	2017-03-23	株式会社新日本科学	抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
JPWO2015108048A1 (ja) *	2014-01-15	2017-03-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10144933B2 (en)	2014-01-15	2018-12-04	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP4137572A1 (en)	2014-01-16	2023-02-22	Wave Life Sciences Ltd.	Chiral design
US11160855B2 (en)	2014-01-21	2021-11-02	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
RU2710393C2 (ru)	2014-01-21	2019-12-26	Пфайзер Инк.	Способ получения иммуногенного конъюгата капсульный полисахарид Streptococcus pneumoniae-белок-носитель
NZ721943A (en)	2014-01-21	2022-07-01	Pfizer	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2015209575A1 (en)	2014-01-21	2016-07-21	Immune Design Corp.	Compositions for use in the treatment of allergic conditions
US20160324949A1 (en)	2014-01-21	2016-11-10	Pfizer Inc.	Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US10279019B2 (en)	2014-02-11	2019-05-07	Stc.Unm	PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
TW201620927A (zh)	2014-02-24	2016-06-16	葛蘭素史密斯克藍生物品公司	Ｕｓｐａ２蛋白質構築體及其用途
WO2015131053A1 (en)	2014-02-28	2015-09-03	Alk-Abelló A/S	Polypeptides derived from phl p and methods and uses thereof for immune response modulation
CA2936286A1 (en)	2014-04-01	2015-10-08	Curevac Ag	Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
EP3134104B1 (en)	2014-04-25	2018-12-26	Tria Bioscience Corp.	Synthetic hapten carrier compositions and methods
CN107073090A (zh)	2014-04-30	2017-08-18	哈佛学院董事会	结合的疫苗装置和杀死癌细胞的方法
US20170121373A1 (en)	2014-05-30	2017-05-04	Sanofi Pasteur Inc.	Expression and conformational analysis of engineered influenza hemagglutinin
EP2952893A1 (en)	2014-06-04	2015-12-09	Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)	Method for detecting antibody-secreting B cells specific for HLA
ES2725948T3 (es)	2014-06-04	2019-09-30	Exicure Inc	Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas
MX384992B (es)	2014-06-13	2025-03-14	Glaxosmithkline Biologicals Sa	Combinaciones inmunógenas.
CA2955015A1 (en)	2014-07-15	2016-01-21	Immune Design Corp.	Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
US10759836B2 (en)	2014-07-18	2020-09-01	University Of Washington	Cancer vaccine compositions and methods of use thereof
AR101256A1 (es)	2014-07-21	2016-12-07	Sanofi Pasteur	Composición vacunal que comprende ipv y ciclodextrinas
WO2016029077A1 (en)	2014-08-22	2016-02-25	Janus Biotherapeutics, Inc.	Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
KR20170063949A (ko)	2014-10-06	2017-06-08	엑시큐어, 인크.	항-ｔｎｆ 화합물
WO2016057921A1 (en)	2014-10-10	2016-04-14	Baker Jr James R	Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
AR102547A1 (es)	2014-11-07	2017-03-08	Takeda Vaccines Inc	Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AU2015252119A1 (en)	2014-11-07	2016-05-26	Takeda Vaccines, Inc.	Hand, foot, and mouth vaccines and methods of manufacture and use thereof
CA2968531A1 (en)	2014-11-21	2016-05-26	Northwestern University	The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
BE1023004A1 (fr)	2014-12-10	2016-10-31	Glaxosmithkline Biologicals Sa	Procede de traitement
EP3233912B1 (en)	2014-12-19	2021-05-19	Regenesance B.V.	Antibodies that bind human c6 and uses thereof
EP3240801B1 (en)	2014-12-31	2021-01-20	Checkmate Pharmaceuticals, Inc.	Combination tumor immunotherapy
JP6647315B2 (ja)	2015-01-09	2020-02-14	イーチュービクスコーポレイション	組み合わせ免疫療法のための方法および組成物
IL252915B2 (en)	2015-01-15	2024-04-01	Pfizer	Immunogenic compositions for use in pneumococcal vaccines
EP3250250A4 (en)	2015-01-30	2019-05-22	President and Fellows of Harvard College	PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
US20180036334A1 (en)	2015-02-13	2018-02-08	Icahn School Of Medicine At Mount Sinai	Rna containing compositions and methods of their use
WO2016140702A1 (en)	2015-03-03	2016-09-09	The United States Of America, As Represented By The Secretary, Department Of Health & Human Serivces	Display platform from bacterial spore coat proteins
CN107530416A (zh)	2015-03-05	2018-01-02	西北大学	非神经侵染的病毒及其用途
EP3268037B1 (en)	2015-03-09	2022-08-31	Celldex Therapeutics, Inc.	Cd27 agonists
JP2018511655A (ja)	2015-03-20	2018-04-26	ザリージェンツオブザユニバーシティオブミシガン	ボルデテラ属に対するワクチン接種における使用のための免疫原性組成物
KR20240145064A (ko)	2015-03-26	2024-10-04	지피앤 백신즈 피티와이 엘티디	연쇄상구균 백신
CN114099793A (zh)	2015-04-10	2022-03-01	哈佛学院院长等	免疫细胞捕获装置及其制备和使用方法
EP3286213B1 (en)	2015-04-20	2021-08-04	Etubics Corporation	Methods and compositions for combination immunotherapy
WO2016180852A1 (en)	2015-05-12	2016-11-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for preparing antigen-specific t cells from an umbilical cord blood sample
CN107847572A (zh)	2015-05-13	2018-03-27	艾吉纳斯公司	用于癌症治疗和预防的疫苗
WO2016191553A1 (en)	2015-05-26	2016-12-01	Ohio State Innovation Foundation	Nanoparticle based vaccine strategy against swine influenza virus
CA2987939A1 (en)	2015-06-02	2016-12-08	Sanofi Pasteur Inc.	Engineered influenza antigenic polypeptides and immunogenic compositions thereof
ES2895148T3 (es)	2015-06-10	2022-02-17	Us Health	Procesos para la producción y purificación de composiciones que contienen ácidos nucleicos
JP2018518511A (ja) *	2015-06-26	2018-07-12	バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＡｎｉｍａｌＨｅａｌｔｈＧｍｂｈ	細胞質ｄｎａ監視分子の調節方法
TWI756893B (zh)	2015-07-21	2022-03-01	美商輝瑞股份有限公司	包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
CA2993076A1 (en)	2015-07-22	2017-01-26	University Of Saskatchewan	Mycoplasma vaccines and uses thereof
US11034752B2 (en)	2015-08-12	2021-06-15	Massachusetts Institute Of Technology	Cell surface coupling of nanoparticles
EP3341017B1 (en)	2015-08-25	2024-10-16	Babita Agrawal	Immunomodulatory compositions comprising caulobacter crescentus and use thereof
CN108024914A (zh)	2015-09-17	2018-05-11	Jrx生物技术有限公司	改善皮肤的水合作用或润湿作用的方法
US10526309B2 (en)	2015-10-02	2020-01-07	The University Of North Carolina At Chapel Hill	Pan-TAM inhibitors and Mer/Axl dual inhibitors
WO2017062246A1 (en)	2015-10-05	2017-04-13	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Human rota virus g9p[6] strain and use as a vaccine
WO2017060857A1 (en)	2015-10-08	2017-04-13	The Governors Of The University Of Alberta	Hepatitis c virus e1/e2 heterodimers and methods of producing same
GB201518668D0 (en)	2015-10-21	2015-12-02	Glaxosmithkline Biolog Sa	Immunogenic Comosition
JP7171433B2 (ja)	2015-10-30	2022-11-15	ザユナイテッドステイツオブアメリカ，アズリプレゼンテッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ	Ｈｅｒ－２発現固形腫瘍の処置のための組成物および方法
JP6884145B2 (ja)	2015-11-20	2021-06-09	ファイザー・インク	肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
US11672866B2 (en)	2016-01-08	2023-06-13	Paul N. DURFEE	Osteotropic nanoparticles for prevention or treatment of bone metastases
DK3407910T3 (da)	2016-01-29	2022-07-18	Bavarian Nordic As	Rekombinant modificeret vaccinia virus ankara (mva)-vaccine mod hesteencephalitisvirus
CN115487351A (zh)	2016-02-06	2022-12-20	哈佛学院校长同事会	重塑造血巢以重建免疫
US20170260286A1 (en)	2016-03-10	2017-09-14	The General Hospital Corporation	Antigen-Binding Fusion Proteins with Modified HSP70 Domains
KR102799265B1 (ko)	2016-03-14	2025-04-23	유니버시티에트 이 오슬로	변경된 FcRn 결합을 갖는 조작된 면역글로불린
WO2017158421A1 (en)	2016-03-14	2017-09-21	University Of Oslo	Anti-viral engineered immunoglobulins
US20190046638A1 (en)	2016-04-01	2019-02-14	Checkmate Pharmaceuticals, Inc.	Fc RECEPTOR-MEDIATED DRUG DELIVERY
MX393066B (es)	2016-04-18	2025-03-24	Celldex Therapeutics Inc	Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
WO2017189448A1 (en)	2016-04-25	2017-11-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bivalent immunogenic conjugate for malaria and typhoid
BR112018073690B1 (pt)	2016-05-16	2022-05-24	Infectious Disease Research Institute	Formulação contendo agonista de tlr e métodos de uso
US11173207B2 (en)	2016-05-19	2021-11-16	The Regents Of The University Of Michigan	Adjuvant compositions
CA3024313A1 (en)	2016-05-21	2017-11-30	Infectious Disease Research Institute	Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
MX2018014602A (es)	2016-05-27	2019-06-10	Etubics Corp	Composiciones de vacunas neoepitopos y metodos de uso de las mismas.
CA3023271A1 (en)	2016-06-01	2017-12-07	Infectious Disease Research Institute	Nanoalum particles containing a sizing agent
MA45165A (fr)	2016-06-02	2019-04-10	Sanofi Pasteur Inc	Polypeptides antigéniques de la grippe modifiés et compositions immunogéniques associées
IL263416B2 (en)	2016-06-03	2024-10-01	Sanofi Pasteur Inc	Modification of transgenic influenza hemagglutinin polypeptides
US10947277B2 (en)	2016-06-13	2021-03-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
JP7185530B2 (ja)	2016-06-13	2022-12-07	トルクセラピューティクス，インコーポレイテッド	免疫細胞機能を促進するための方法および組成物
GB201610599D0 (en)	2016-06-17	2016-08-03	Glaxosmithkline Biologicals Sa	Immunogenic Composition
EP3471761A2 (en)	2016-06-21	2019-04-24	University Of Oslo	Hla binding vaccine moieties and uses thereof
US10632185B2 (en)	2016-07-08	2020-04-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chimeric west nile/zika viruses and methods of use
US11344615B2 (en)	2016-07-08	2022-05-31	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Nucleic acids encoding chimeric dengue/Zika viruses optimized for growth and stability in vero cells
CA3030427A1 (en)	2016-07-13	2018-01-18	President And Fellows Of Harvard College	Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
JP7274214B2 (ja)	2016-08-02	2023-05-16	プレジデントアンドフェローズオブハーバードカレッジ	免疫応答を調節するための生体材料
JP7001686B2 (ja)	2016-08-05	2022-02-04	サノフィパスツールインコーポレイティッド	多価肺炎球菌多糖体－タンパク質コンジュゲート組成物
CN109862908B (zh)	2016-08-05	2023-05-02	圣诺菲·帕斯图尔公司	多价肺炎球菌多糖-蛋白质缀合物组合物
EP3504230A1 (en)	2016-08-23	2019-07-03	GlaxoSmithKline Biologicals SA	Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
WO2018039629A2 (en)	2016-08-25	2018-03-01	Northwestern University	Micellar spherical nucleic acids from thermoresponsive, traceless templates
US11801290B2 (en)	2016-09-16	2023-10-31	Access To Advanced Health Institute	Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
BE1024774B1 (fr)	2016-09-29	2018-07-02	Glaxosmithkline Biologicals Sa	Compositions et procedes de traitement
WO2018065622A1 (en) *	2016-10-07	2018-04-12	Secarna Pharmaceuticals Gmbh & Co Kg	Immunosuppression-reverting oligonucleotides inhibiting the expression of cd39
US10172933B2 (en)	2016-10-31	2019-01-08	The United States Of America, As Represented By The Secretary Of Agriculture	Mosaic vaccines for serotype a foot-and-mouth disease virus
WO2018096396A1 (en)	2016-11-22	2018-05-31	University Of Oslo	Albumin variants and uses thereof
GB201620968D0 (en)	2016-12-09	2017-01-25	Glaxosmithkline Biologicals Sa	Adenovirus polynucleotides and polypeptides
US11084850B2 (en)	2016-12-16	2021-08-10	The Pirbright Institute	Recombinant prefusion RSV F proteins and uses thereof
AU2018208844B2 (en)	2017-01-20	2021-02-25	Pfizer Inc.	Immunogenic compositions for use in pneumococcal vaccines
WO2018160865A1 (en)	2017-03-01	2018-09-07	Charles Jeffrey Brinker	Active targeting of cells by monosized protocells
WO2018162450A1 (en)	2017-03-06	2018-09-13	Fundación Para La Investigación Médica Aplicada	New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
WO2018178265A1 (en)	2017-03-31	2018-10-04	Glaxosmithkline Intellectual Property Development Limited	Immunogenic composition, use and method of treatment
WO2018178264A1 (en)	2017-03-31	2018-10-04	Glaxosmithkline Intellectual Property Development Limited	Immunogenic composition, use and method of treatment
WO2018193063A2 (en)	2017-04-19	2018-10-25	Institute For Research In Biomedicine	Novel malaria vaccines and antibodies binding to plasmodium sporozoites
US11696954B2 (en)	2017-04-28	2023-07-11	Exicure Operating Company	Synthesis of spherical nucleic acids using lipophilic moieties
US20200115324A1 (en)	2017-06-11	2020-04-16	Molecular Express, Inc.	Methods and compositions for substance use disorder vaccine formulations and uses thereof
KR20240096685A (ko)	2017-06-15	2024-06-26	액세스 투 어드밴스드 헬스 인스티튜트	나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
WO2019018744A1 (en)	2017-07-21	2019-01-24	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	IMMUNOGENIC COMPOSITIONS OF NEISSERIA MENINGITIDIS
BR112020001768A2 (pt)	2017-08-14	2020-09-29	Glaxosmithkline Biologicals S.A.	método de reforçar uma resposta imune pré-existente contra haemophilus influenzae e moraxella catarrhalis não tipáveis em um indivíduo, e, protocolo de vacinação.
US11123415B2 (en)	2017-08-16	2021-09-21	Ohio State Innovation Foundation	Nanoparticle compositions for Salmonella vaccines
CA3074826A1 (en)	2017-09-05	2019-03-14	Torque Therapeutics, Inc.	Therapeutic protein compositions and methods of making and using the same
US12005112B2 (en)	2017-09-07	2024-06-11	University Of Oslo	Vaccine molecules
US12268736B2 (en)	2017-09-07	2025-04-08	University Of Oslo	Vaccine molecules
WO2019048631A1 (en)	2017-09-08	2019-03-14	Mina Therapeutics Limited	SMALL HNF4A ACTIVATOR RNA COMPOSITIONS AND METHODS OF USE
CN111315406A (zh)	2017-09-08	2020-06-19	传染病研究所	包括皂苷的脂质体调配物及其使用方法
CA3081436A1 (en)	2017-10-31	2019-05-09	Western Oncolytics Ltd.	Platform oncolytic vector for systemic delivery
CA3081581A1 (en)	2017-11-03	2019-05-09	Takeda Vaccines, Inc.	Method for inactivating zika virus and for determining the completeness of inactivation
US11235046B2 (en)	2017-11-04	2022-02-01	Nevada Research & Innovation Corporation	Immunogenic conjugates and methods of use thereof
JP7770769B2 (ja) *	2017-12-15	2025-11-17	エランコアニマルヘルスゲー・エム・ベー・ハー	免疫刺激性オリゴヌクレオチド
US11116830B2 (en)	2017-12-18	2021-09-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bacterial polysaccharide-conjugated carrier proteins and use thereof
KR20200101954A (ko)	2017-12-19	2020-08-28	메사추세츠 인스티튜트 오브 테크놀로지	항원-아주반트 커플링 시약 및 사용 방법
GB201721576D0 (en)	2017-12-21	2018-02-07	Glaxosmithkline Biologicals Sa	Hla antigens and glycoconjugates thereof
GB201721582D0 (en)	2017-12-21	2018-02-07	Glaxosmithkline Biologicals Sa	S aureus antigens and immunogenic compositions
US11369675B2 (en)	2018-01-22	2022-06-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Broadly protective inactivated influenza virus vaccine
CN111836639A (zh)	2018-01-26	2020-10-27	河谷细胞有限公司	用于联合癌症疫苗和免疫辅助疗法的组合物和方法
KR102812816B1 (ko)	2018-02-05	2025-05-27	사노피 파스퇴르 인코포레이티드	다가 폐렴구균성 다당류-단백질 접합체 조성물
US12246031B2 (en)	2018-02-13	2025-03-11	Checkmate Pharmaceuticals, Inc.	Compositions and methods for tumor immunotherapy
JP2021513840A (ja)	2018-02-16	2021-06-03	２エーファーマアーベー	自己免疫疾患の処置のためのパルボウイルス構造タンパク質
EP3527223A1 (en)	2018-02-16	2019-08-21	2A Pharma AB	Mutated parvovirus structural protein
BR112020016859A2 (pt)	2018-02-28	2020-12-29	Pfizer Inc.	Variantes de il-15 e usos da mesma
US11633471B2 (en)	2018-03-06	2023-04-25	Unm Rainforest Innovations	Compositions and methods for reducing serum triglycerides
ES2973078T3 (es)	2018-03-28	2024-06-18	Sanofi Pasteur Inc	Métodos de generación de composiciones de vacuna ampliamente protectoras que comprenden hemaglutinina
EP3773703A1 (en)	2018-04-03	2021-02-17	Sanofi	Antigenic influenza-ferritin polypeptides
EP3773708A2 (en)	2018-04-03	2021-02-17	Sanofi	Antigenic epstein barr virus polypeptides
CN112584858A (zh)	2018-04-03	2021-03-30	赛诺菲	抗原性ospa多肽
CA3095175A1 (en)	2018-04-03	2019-10-10	Sanofi	Antigenic respiratory syncytial virus polypeptides
CN112512564A (zh)	2018-04-03	2021-03-16	赛诺菲	铁蛋白蛋白
AU2019251421B2 (en)	2018-04-09	2025-05-01	Checkmate Pharmaceuticals	Packaging oligonucleotides into virus-like particles
AU2019256383A1 (en)	2018-04-17	2020-11-26	Celldex Therapeutics, Inc.	Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
KR102584675B1 (ko)	2018-05-23	2023-10-05	화이자 인코포레이티드	GUCY2c에 특이적인 항체 및 이의 용도
SG11202010580TA (en)	2018-05-23	2020-12-30	Pfizer	Antibodies specific for cd3 and uses thereof
MX2020013553A (es)	2018-06-12	2021-02-26	Glaxosmithkline Biologicals Sa	Polinucleotidos y polipeptidos de adenovirus.
US12161712B2 (en)	2018-07-13	2024-12-10	University Of Georgia Research Foundation	Broadly reactive immunogens of influenza H3 virus, compositions and methods of use thereof
JP7446279B2 (ja)	2018-07-19	2024-03-08	グラクソスミスクラインバイオロジカルズソシエテアノニム	乾燥多糖を調製するための方法
JP2021533162A (ja)	2018-08-07	2021-12-02	グラクソスミスクラインバイオロジカルズソシエテアノニム	プロセス及びワクチン
US11260119B2 (en)	2018-08-24	2022-03-01	Pfizer Inc.	Escherichia coli compositions and methods thereof
US12239699B2 (en)	2018-09-11	2025-03-04	Shanghai Public Health Clinical Center	Immunogen for broad-spectrum influenza vaccine and application thereof
WO2020061129A1 (en)	2018-09-19	2020-03-26	President And Fellows Of Harvard College	Compositions and methods for labeling and modulation of cells in vitro and in vivo
US12252708B2 (en)	2018-09-24	2025-03-18	Unm Rainforest Innovations	Living mammalian cells modified with functional modular nanoparticles
CN113454100B (zh)	2018-12-04	2024-08-23	洛克菲勒大学	Hiv疫苗免疫原
US20220000779A1 (en)	2018-12-06	2022-01-06	Glaxosmithkline Biologicals Sa	Immunogenic compositions
US20220023413A1 (en)	2018-12-12	2022-01-27	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
EP3893926A1 (en)	2018-12-12	2021-10-20	Pfizer Inc.	Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
US20220054632A1 (en)	2018-12-12	2022-02-24	Glaxosmithkline Biologicals Sa	Modified carrier proteins for o-linked glycosylation
WO2020123989A1 (en)	2018-12-14	2020-06-18	University Of Georgia Research Foundation, Inc.	Crimean-congo hemorrhagic fever virus replicon particles and use thereof
EP3897846A1 (en)	2018-12-21	2021-10-27	GlaxoSmithKline Biologicals SA	Methods of inducing an immune response
US20220370606A1 (en)	2018-12-21	2022-11-24	Pfizer Inc.	Combination Treatments Of Cancer Comprising A TLR Agonist
GB201901608D0 (en)	2019-02-06	2019-03-27	Vib Vzw	Vaccine adjuvant conjugates
US12208164B2 (en)	2019-02-28	2025-01-28	Unm Rainforest Innovations	Modular metal-organic polyhedra superassembly compositions
CN114269373A (zh)	2019-04-02	2022-04-01	赛诺菲	抗原性多聚呼吸道合胞病毒多肽
CA3136278A1 (en)	2019-04-10	2020-10-15	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2020212461A1 (en)	2019-04-18	2020-10-22	Glaxosmithkline Biologicals Sa	Antigen binding proteins and assays
PH12021552736A1 (en)	2019-05-20	2022-07-11	Valneva Se	A subunit vaccine for treatment or prevention of a respiratory tract infection
CA3141577A1 (en)	2019-05-25	2020-12-03	Infectious Disease Research Institute	Composition and method for spray drying an adjuvant vaccine emulsion
WO2020240268A1 (en)	2019-05-31	2020-12-03	Universidad De Chile	An immunogenic formulation that induces protection against shiga toxin-producing escherichia coli (stec)
EP3770269A1 (en)	2019-07-23	2021-01-27	GlaxoSmithKline Biologicals S.A.	Quantification of bioconjugate glycosylation
MX2022001488A (es)	2019-08-05	2022-03-02	Glaxosmithkline Biologicals Sa	Composicion inmunogenica.
EP4021894A1 (en)	2019-08-30	2022-07-06	University of Rochester	Septin inhibitors for treatment of cancers
AU2020351168A1 (en)	2019-09-18	2022-04-14	Children's Medical Center Corporation	An anaplastic lymphoma kinase (ALK) cancer vaccine and methods of use
EP3799884A1 (en)	2019-10-01	2021-04-07	GlaxoSmithKline Biologicals S.A.	Immunogenic compositions
MX2022005252A (es)	2019-11-01	2022-06-08	Pfizer	Composiciones de escherichia coli y metodos de las mismas.
EP4058581A1 (en)	2019-11-15	2022-09-21	Infectious Disease Research Institute	Rig-i agonist and adjuvant formulation for tumor treatment
MX2022006054A (es)	2019-11-22	2022-06-24	Glaxosmithkline Biologicals Sa	Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos.
US20230039456A1 (en)	2019-12-17	2023-02-09	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Live attenuated leishmania parasite vaccines with enhanced safety characteristics
CN115397853A (zh)	2019-12-17	2022-11-25	辉瑞大药厂	对cd47、pd-l1具特异性的抗体及其用途
BR112022014555A2 (pt)	2020-02-23	2022-09-20	Pfizer	Composições de escherichia coli e métodos das mesmas.
JP2023515829A (ja)	2020-02-28	2023-04-14	サノフィパスツールインコーポレイテッド	小児対象のための高用量インフルエンザワクチン
US11213482B1 (en)	2020-03-05	2022-01-04	University of Pittsburgh—Of the Commonwealth System of Higher Educat	SARS-CoV-2 subunit vaccine and microneedle array delivery system
CA3176303A1 (en)	2020-04-20	2021-10-28	Antonio FACCIUOLO	Compositions and methods for preventing, controlling and diagnosing mycobacterial infections
JP2023533793A (ja)	2020-07-17	2023-08-04	ファイザー・インク	治療用抗体およびそれらの使用
CA3174411A1 (en)	2020-09-04	2022-03-10	Ryan M. Kramer	Co-lyophilized rna and nanostructured lipid carrier
JP2023542528A (ja)	2020-09-24	2023-10-10	フレッドハッチンソンキャンサーセンター	Ｓｏｘ２抗原を標的とする免疫療法
WO2022066973A1 (en)	2020-09-24	2022-03-31	Fred Hutchinson Cancer Research Center	Immunotherapy targeting pbk or oip5 antigens
CA3194598A1 (en)	2020-10-07	2022-04-14	Valentina SCREPANTI-SUNDQUIST	Cholera vaccine formulation
WO2022083768A1 (zh)	2020-10-23	2022-04-28	江苏省疾病预防控制中心(江苏省公共卫生研究院)	免疫原性组合物及其应用
WO2024110839A2 (en)	2022-11-22	2024-05-30	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12138302B2 (en)	2020-10-27	2024-11-12	Pfizer Inc.	Escherichia coli compositions and methods thereof
CA3199610A1 (en)	2020-10-27	2022-05-05	Pfizer Inc.	Escherichia coli compositions and methods thereof
KR20230097160A (ko)	2020-11-04	2023-06-30	화이자 인코포레이티드	폐렴구균 백신에 사용하기 위한 면역원성 조성물
WO2022101745A2 (en)	2020-11-10	2022-05-19	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202227621A (zh)	2020-11-19	2022-07-16	美商凱立凡爾免疫治療股份有限公司	重塑腫瘤微環境的溶瘤免疫療法
US12357681B2 (en)	2020-12-23	2025-07-15	Pfizer Inc.	E. coli FimH mutants and uses thereof
CA3173408A1 (en)	2020-12-23	2022-06-30	Access To Advanced Health Institute	Solanesol vaccine adjuvants and methods of preparing same
US20240299510A1 (en)	2020-12-31	2024-09-12	The United States Of America,As Represented By The Secretary,Department Of Health And Human Services	Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
EP4294433A1 (en)	2021-02-22	2023-12-27	GlaxoSmithKline Biologicals SA	Immunogenic composition, use and methods
EP4313132A1 (en)	2021-03-31	2024-02-07	Vib Vzw	Vaccine compositions for trypanosomatids
EP4319802A2 (en)	2021-04-09	2024-02-14	Valneva SE	Human metapneumovirus combination vaccine
WO2022217019A1 (en)	2021-04-09	2022-10-13	Celldex Therapeutics, Inc.	Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
WO2022232375A1 (en)	2021-04-30	2022-11-03	Kalivir Immunotherapeutics, Inc.	Oncolytic viruses for modified mhc expression
EP4346893A2 (en)	2021-05-28	2024-04-10	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20230175284A (ko)	2021-05-28	2023-12-29	화이자 인코포레이티드	접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
MX2024000330A (es)	2021-07-16	2024-01-25	Univ Illinois	Vacuna universal para virus de influenza en base a la proteina m2 tetramerica incorporada en nanodiscos.
WO2023018817A1 (en)	2021-08-11	2023-02-16	Sanofi Pasteur Inc.	Truncated influenza neuraminidase and methods of using the same
IL311964A (en)	2021-10-08	2024-06-01	Sanofi Pasteur Inc	Multivalent influenza vaccines
KR20240105413A (ko)	2021-11-05	2024-07-05	사노피	헤마글루티닌과 뉴라미니다제를 포함하는 하이브리드 다가 인플루엔자 백신 및 이의 사용 방법
WO2023079507A1 (en)	2021-11-05	2023-05-11	Sanofi	Respiratory syncytial virus rna vaccine
IL312545A (en)	2021-11-05	2024-07-01	Sanofi Pasteur Inc	Multivalent Influenza Vaccines Including Hemagglutinin and Recombinant Neuraminidase and Methods of Using Them
WO2023077521A1 (en)	2021-11-08	2023-05-11	Celldex Therapeutics, Inc	Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023083964A1 (en)	2021-11-11	2023-05-19	2A Pharma Ab	Parvovirus structural protein against beta- and gamma-hpv
MX2024006506A (es)	2021-11-30	2024-08-14	Sanofi Pasteur Inc	Vacunas basadas en vectores virales de metapneumovirus humano.
IL312997A (en)	2021-11-30	2024-07-01	Sanofi Pasteur Inc	Human metapneumovirus vaccines
CN118510790A (zh)	2021-12-13	2024-08-16	美国政府(由卫生和人类服务部的部长所代表)	噬菌体λ-疫苗系统
EP4448103A1 (en)	2021-12-17	2024-10-23	Sanofi	Lyme disease rna vaccine
IL314243A (en)	2022-01-13	2024-09-01	Pfizer	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4469565A1 (en)	2022-01-27	2024-12-04	Sanofi Pasteur	Modified vero cells and methods of using the same for virus production
WO2023161817A1 (en)	2022-02-25	2023-08-31	Pfizer Inc.	Methods for incorporating azido groups in bacterial capsular polysaccharides
US20250191693A1 (en)	2022-03-14	2025-06-12	Sanofi Pasteur, Inc.	Machine-learning techniques in protein design for vaccine generation
KR20250008765A (ko)	2022-05-06	2025-01-15	사노피	핵산 백신에 대한 신호 서열
CA3256617A1 (en)	2022-05-11	2023-11-16	Pfizer Inc.	PROCESS FOR PRODUCING VACCINE FORMULATIONS WITH PRESERVATIVES
US20250213667A1 (en)	2022-06-01	2025-07-03	Valneva Austria Gmbh	Clostridium difficile vaccine
KR20250029868A (ko)	2022-06-29	2025-03-05	버베리안 노딕 에이/에스	재조합 변형 saRNA (VRP) 및 백시니아 바이러스 안카라 (MVA) 프라임-부스트 요법
CA3266697A1 (en)	2022-09-09	2024-03-14	Access To Advanced Health Institute	COMPOSITION OF AN IMMUNOGENEOUS VACCINE CONTAINING A SAPONIN
JP2025537539A (ja)	2022-11-04	2025-11-18	サノフィパスツールインコーポレイテッド	呼吸器合胞体ウイルスｒｎａワクチン接種
WO2024110827A1 (en)	2022-11-21	2024-05-30	Pfizer Inc.	Methods for preparing conjugated capsular saccharide antigens and uses thereof
EP4626405A1 (en)	2022-12-01	2025-10-08	Pfizer Inc.	Pneumococcal conjugate vaccine formulations
WO2024121380A1 (en)	2022-12-08	2024-06-13	Pierre Fabre Medicament	Vaccinal composition and adjuvant
CN120475988A (zh)	2022-12-13	2025-08-12	辉瑞公司	免疫原性组合物及引发针对艰难梭菌的免疫应答的方法
TW202438514A (zh)	2022-12-20	2024-10-01	法商賽諾菲公司	鼻病毒mrna疫苗
IL321887A (en)	2023-01-12	2025-09-01	Bavarian Nordic As	Recombinantly modified Sarna (vrp) for cancer vaccine
WO2024163327A1 (en)	2023-01-30	2024-08-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Epstein-barr virus glycoprotein 42 immunogens for vaccination and antibody discovery
WO2024166008A1 (en)	2023-02-10	2024-08-15	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202502375A (zh)	2023-03-02	2025-01-16	法商賽諾菲公司	用於治療披衣菌之組合物
KR20250167153A (ko)	2023-03-03	2025-11-28	셀덱스 쎄라퓨틱스, 인크.	항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물
CN121038808A (zh)	2023-03-30	2025-11-28	辉瑞公司	包含缀合的荚膜糖抗原的免疫原性组合物及其用途
WO2024214016A1 (en)	2023-04-14	2024-10-17	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en)	2023-04-24	2024-10-31	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202500750A (zh)	2023-05-05	2025-01-01	法商賽諾菲公司	用於治療痤瘡的組成物
AR132662A1 (es)	2023-05-10	2025-07-16	Sanofi Sa	Combinación de vacunas respiratorias de arnm
TW202508621A (zh)	2023-05-11	2025-03-01	美商賽諾菲巴斯德公司	呼吸道融合病毒疫苗及其使用方法
WO2024241172A2 (en)	2023-05-19	2024-11-28	Glaxosmithkline Biologicals Sa	Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2024246358A1 (en)	2023-06-01	2024-12-05	Sanofi	Thermostable compositions comprising mrna lipid nanoparticles
WO2025006737A1 (en)	2023-06-30	2025-01-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
AR133317A1 (es)	2023-07-19	2025-09-17	Sanofi Sa	Constructos antigénicos de porphyromonas gingivalis
TW202527960A (zh)	2023-09-06	2025-07-16	美商賽諾菲巴斯德公司	經修飾ｂ型流感血球凝集素多肽及核酸及其用途
WO2025057078A1 (en)	2023-09-14	2025-03-20	Pfizer Inc.	Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025106787A1 (en)	2023-11-17	2025-05-22	Sanofi Pasteur Inc.	Trehalose vaccine formulation
WO2025133971A1 (en)	2023-12-23	2025-06-26	Pfizer Inc.	Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025163460A2 (en)	2024-01-30	2025-08-07	Pfizer Inc.	Vaccines against respiratory diseases
WO2025186705A2 (en)	2024-03-06	2025-09-12	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20250281605A1 (en)	2024-03-08	2025-09-11	Sanofi	Antigenic Epstein Barr Virus Polypeptides
WO2025191415A1 (en)	2024-03-11	2025-09-18	Pfizer Inc.	Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025210592A1 (en)	2024-04-05	2025-10-09	Sanofi Pasteur Inc.	Muscle cell lnp-mrna quality control assays
WO2025219904A1 (en)	2024-04-19	2025-10-23	Pfizer Inc.	Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
WO2025238502A1 (en)	2024-05-14	2025-11-20	Pfizer Inc.	Aluminum adjuvant nanoparticles, methods of manufacture, and uses thereof
WO2025257712A1 (en)	2024-06-12	2025-12-18	Pfizer Inc.	Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2034118A1 (en) †	1970-07-09	1972-01-13	Seinfeld, Hugo, Brendel, Walter, Prof Dr . 8000 München	Xenogenic nucleic acids for enhancing antigenicity - of peptides and proteins
US4956296A (en) *	1987-06-19	1990-09-11	Genex Corporation	Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G
US5059519A (en) *	1986-07-01	1991-10-22	University Of Massachusetts Medical School	Oligonucleotide probes for the determination of the proclivity for development of autoimmune diseases
CA1339596C (en)	1987-08-07	1997-12-23	New England Medical Center Hospitals, Inc.	Viral expression inhibitors
US5786189A (en) *	1989-11-29	1998-07-28	Smithkline Beecham Biologicals (S.A.)	Vaccine
US5248670A (en)	1990-02-26	1993-09-28	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides for inhibiting herpesviruses
EP0468520A3 (en) *	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
JPH04352724A (ja) *	1990-07-27	1992-12-07	Mitsui Toatsu Chem Inc	免疫調節型治療剤
EP0544713B1 (en)	1990-08-16	1997-07-02	Isis Pharmaceuticals, Inc.	Oligonucleotides for modulating the effects of cytomegalovirus infections
US5234811A (en) *	1991-09-27	1993-08-10	The Scripps Research Institute	Assay for a new gaucher disease mutation
CA2122132A1 (en) *	1991-11-18	1993-05-27	Tse Wen Chang	Anti-sense oligonucleotides for isotype-specific suppression of immunoglobulin production
US5585479A (en) *	1992-07-24	1996-12-17	The United States Of America As Represented By The Secretary Of The Navy	Antisense oligonucleotides directed against human ELAM-I RNA
US5466705A (en)	1992-07-24	1995-11-14	Kumiai Chemical Industry Co., Ltd.	Triazole derivatives pest controlling agent and pest control method
RU95104940A (ru) †	1992-07-27	1997-01-10	Хайбрайдон	Способ введения в олигонуклеотид алкилфосфонотиоатной или арилфосфонотиоатной межнуклеотидной связи, способ получения олигонуклеотида, олигонуклеотиды, способ ингибирования генной экспрессии, способ лечения
US5840497A (en) *	1993-06-11	1998-11-24	The Commonwealth Of Australia Commonwealth Scientific And Industrial Research Organization	Method for specific silencing of genes by DNA methylation
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
CA2560114A1 (en) *	1994-07-15	1996-02-01	The University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
US5629052A (en)	1995-02-15	1997-05-13	The Procter & Gamble Company	Method of applying a curable resin to a substrate for use in papermaking

1995
- 1995-02-07 CA CA002560114A patent/CA2560114A1/en not_active Abandoned
- 1995-02-07 EP EP01202811A patent/EP1167377B2/en not_active Expired - Lifetime
- 1995-02-07 DK DK95911630.2T patent/DK0772619T4/da active
- 1995-02-07 ES ES01202813T patent/ES2366201T3/es not_active Expired - Lifetime
- 1995-02-07 PT PT95911630T patent/PT772619E/pt unknown
- 1995-02-07 WO PCT/US1995/001570 patent/WO1996002555A1/en not_active Ceased
- 1995-02-07 DE DE69535036T patent/DE69535036T3/de not_active Expired - Lifetime
- 1995-02-07 ES ES01202811T patent/ES2320315T5/es not_active Expired - Lifetime
- 1995-02-07 DE DE69535905T patent/DE69535905D1/de not_active Expired - Lifetime
- 1995-02-07 EP EP95911630A patent/EP0772619B2/en not_active Expired - Lifetime
- 1995-02-07 ES ES95911630T patent/ES2267100T5/es not_active Expired - Lifetime
- 1995-02-07 US US08/386,063 patent/US6194388B1/en not_active Expired - Lifetime
- 1995-02-07 AT AT01202811T patent/ATE420171T1/de not_active IP Right Cessation
- 1995-02-07 JP JP50499196A patent/JP3468773B2/ja not_active Expired - Lifetime
- 1995-02-07 CA CA002194761A patent/CA2194761C/en not_active Expired - Lifetime
- 1995-02-07 EP EP01202813A patent/EP1167378B1/en not_active Expired - Lifetime
- 1995-02-07 AT AT95911630T patent/ATE328890T1/de active
- 1995-02-07 AU AU19127/95A patent/AU713040B2/en not_active Expired
- 1995-02-07 AT AT01202813T patent/ATE509102T1/de not_active IP Right Cessation
- 1995-02-07 EP EP01202814A patent/EP1167379A3/en not_active Ceased
2002
- 2002-05-13 HK HK02103584.4A patent/HK1043598A1/en unknown
- 2002-06-26 HK HK02104747.6A patent/HK1044950A1/en not_active IP Right Cessation
- 2002-06-26 HK HK02104746.7A patent/HK1044949B/en not_active IP Right Cessation
- 2002-10-16 JP JP2002302338A patent/JP2003144184A/ja not_active Withdrawn
2003
- 2003-06-23 JP JP2003178741A patent/JP4126252B2/ja not_active Expired - Lifetime
- 2003-06-23 JP JP2003178740A patent/JP2004024261A/ja not_active Withdrawn
2004
- 2004-03-11 JP JP2004069838A patent/JP2004215670A/ja not_active Withdrawn
2008
- 2008-01-25 JP JP2008015654A patent/JP2008169216A/ja not_active Withdrawn
2009
- 2009-03-10 JP JP2009057160A patent/JP2009148296A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP1167378A2 (en)	2002-01-02
ES2267100T5 (es)	2011-04-08
DE69535036D1 (de)	2006-07-20
JP2004215670A (ja)	2004-08-05
CA2194761A1 (en)	1996-02-01
EP0772619B2 (en)	2010-12-08
JP3468773B2 (ja)	2003-11-17
EP1167377A3 (en)	2004-09-08
DE69535036T2 (de)	2007-01-18
EP1167377B2 (en)	2012-08-08
EP1167377B1 (en)	2009-01-07
EP1167379A3 (en)	2004-09-08
HK1044949B (en)	2012-01-27
DK0772619T3 (da)	2006-10-09
JP2004043466A (ja)	2004-02-12
ATE420171T1 (de)	2009-01-15
ES2366201T3 (es)	2011-10-18
HK1043598A1 (en)	2002-09-20
ES2320315T3 (es)	2009-05-21
EP1167378A3 (en)	2005-08-17
US6194388B1 (en)	2001-02-27
JP2009148296A (ja)	2009-07-09
JP2008169216A (ja)	2008-07-24
CA2560114A1 (en)	1996-02-01
EP0772619B1 (en)	2006-06-07
DE69535036T3 (de)	2011-07-07
DE69535905D1 (de)	2009-02-26
EP1167378B1 (en)	2011-05-11
JP4126252B2 (ja)	2008-07-30
ATE328890T1 (de)	2006-06-15
ATE509102T1 (de)	2011-05-15
WO1996002555A1 (en)	1996-02-01
EP1167379A2 (en)	2002-01-02
JP2004024261A (ja)	2004-01-29
EP0772619A1 (en)	1997-05-14
HK1044949A1 (en)	2002-11-08
AU713040B2 (en)	1999-11-18
ES2267100T3 (es)	2007-03-01
EP1167377A2 (en)	2002-01-02
JP2003144184A (ja)	2003-05-20
JPH10506265A (ja)	1998-06-23
ES2320315T5 (es)	2012-12-05
AU1912795A (en)	1996-02-16
HK1044950A1 (en)	2002-11-08
DK0772619T4 (da)	2011-02-21
CA2194761C (en)	2006-12-19

Publication	Publication Date	Title
DE69535036D1 (de)	2006-07-20	Immunomodulatorische oligonukleotide
ZA9811848B (en)	2000-06-26	Vaccine.
ZA988789B (en)	2000-03-29	Vaccine.
DE69727183D1 (de)	2004-02-19	Angetriebenes Handstück
EP0666057A3 (en)	1995-10-18	Surgical stapling device.
EP0674876A3 (en)	1995-12-27	Surgical stapling instrument.
ZA929194B (en)	1993-05-24	Polymeric surgical staple.
ZA9811585B (en)	2000-06-19	Medical device.
IS4812A (is)	1998-07-28	Samsett meðferð fyrir beingisnun
IT1292837B1 (it)	1999-02-11	Apparecchio chirurgico per biopsia.
DZ2283A1 (fr)	2002-12-25	Composition de vaccin.
ZA973642B (en)	1997-11-25	DNA vaccine formulations.
IT1302338B1 (it)	2000-09-05	Dispositivo per l'azionamento del freno di un veicolo.
ZA971250B (en)	1997-08-27	Dental syringe.
ZA9710606B (en)	1998-06-12	Non-virulent Mycoplasma synoviae vaccine thereof.
FI965196L (fi)	1996-12-23	HIV-infektion yhdistelmähoito
ZA9810445B (en)	1999-07-01	Novel bone surgical device.
ZA984696B (en)	1999-01-04	Vaccine compositions V.
ES1027473Y (es)	1995-02-16	Boton quirurgico de traccion ortodoncia.
ITBO930113V0 (it)	1993-05-19	supporto per strumenti odontoiatrici accessori.
ES1028663Y (es)	1995-07-01	Depresor lingual.
IT1274909B (it)	1997-07-25	Manipolo endoorale per riprese di video-immagini.
ITBO970084A0 (it)	1997-02-21	Manipolo dentale per la rimozione del tartaro.
ES1030157Y (es)	1996-01-16	Depresor lingual.
BR9401338A (pt)	1995-10-24	Bocal para lâmpadas de encaixe por pressão das mesmas